

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 December 2005 (08.12.2005)

PCT

(10) International Publication Number
WO 2005/115382 A1

(51) International Patent Classification⁷: **A61K 31/415**,
31/454, A61P 29/00, 43/00

[NO/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970
Hoersholm (DK).

(21) International Application Number:
PCT/EP2005/005884

(74) Agent: **WALLS, Alan, James**; PO Box 223, Tadworth,
Surrey KT20 5SS (GB).

(22) International Filing Date: 30 May 2005 (30.05.2005)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0412198.4 29 May 2004 (29.05.2004) GB
0414196.6 24 June 2004 (24.06.2004) GB
0424018.0 29 October 2004 (29.10.2004) GB

(71) Applicant (for all designated States except US): **7TM
PHARMA A/S** [DK/DK]; Fremtidsvej 3, DK-2970 Hoersholm (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ULVEN, Trond**
[NO/DK]; 7TM Pharma A/S, Fremtidsvej 3, DK-2970
Hoersholm (DK). **FRIMURER, Thomas** [DK/DK]; 7TM
Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm (DK).
RIST, Øystein [NO/DK]; 7TM Pharma A/S, Fremtidsvej
3, DK-2970 Hoersholm (DK). **KOSTENIS, Evi** [DE/DK];
7TM Pharma A/S, Fremtidsvej 3, DK-2970 Hoersholm
(DK). **HÖGBERG, Thomas** [SE/SE]; 7TM Pharma A/S,
Fremtidsvej 3, DK-2970 Hoersholm (DK). **RECEVEUR,
Jean-Marie** [FR/DK]; 7TM Pharma A/S, Fremtidsvej
3, DK-2970 Hoersholm (DK). **GRIMSTRUP, Marie**


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES



(57) Abstract: Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group -COON, or a carboxyl bioisostere; A₁ is hydrogen or methyl; ring Ar¹ is an optionally substituted phenyl ring 5- or 6-membered monocyclic heteroaryl ring, in which AA₁CHO- and L2 are linked to adjacent ring

atoms; rings Ar², Ar³ each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.

CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES

This invention relates to the use of a class of compounds which are ligands of the CRTH2 receptor (Chemoattractant Receptor-homologous molecule expressed on T Helper cells type 2), in the treatment of diseases responsive to modulation of CRTH2 receptor activity, principally diseases having a significant inflammatory component. The invention also relates to novel members of that class of ligands and pharmaceutical compositions containing them.

Many classes of antiinflammatory agents are known, including the non-steroidal antiinflammatory compounds known as NSAIDs and the inhibitors of cyclooxygenase (COX-1 and COX-2). Benzoylphenylacetic acid and some benzophenone derivatives with carboxymethoxy substituents in one of the rings have been identified as antiinflammatory agents (see, for example, Khanum et. al. Bioorganic Chemistry Vol 32, No. 4, 2004, pages 211-222 and the references cited therein). Some o-phenyl carbamoyl-phenoxyacetic acids and o-benzamido-phenoxyethyl tetrazoles have been reported as potential antiinflammatory agent, see for example Drain et. al. J. Pharm. Pharmac., 1971, 23, 857-864, and ibid 1970, 22, 684-693. WO 99/15520 discloses a few benzophenone derivatives with carboxymethoxy or tetrazolylmethoxy substituents in one of the rings, synthesised as members of a group of compounds said to have activity as inhibitors of peroxisome proliferator-activated receptor (PPAR), and utility in a variety of disease states including diabetes, cardiac disease, and circulatory disease.


The natural ligand of the G-protein coupled receptor CRTH2 is prostaglandin D2. As its name implies, CRTH2 is expressed on T helper cells type 2 (Th2 cells) but it is also known to be expressed on eosinophils and basophil cells. Cell activation as a result of binding of PGD2 to the CRTH2 receptor results in a complex biological response, including release of inflammatory mediators. Elevated levels of PGD2 are therefore associated with many diseases which have a strong inflammatory component, such as asthma, rhinitis and allergies. Blocking binding of PGD2 to the CRTH2 receptor is therefore a useful therapeutic strategy for treatment of such diseases.

Some small molecule ligands of CRTH2, apparently acting as antagonists of PGD2, are known, for example as proposed in the following patent publications: WO

03/097042, WO 03/097598, WO 03/066046, WO 03/066047, WO 03/101961, WO 03/101981, GB 2388540, WO 04/089885 and WO 05/018529.

The structures of PGD2 antagonist compounds referred to in some of the foregoing publications have a bicyclic or tricyclic core ring system related to the indole core of indomethacin, a known anti-inflammatory agent, now known to bind to CRTH2. The present invention arises from the identification of a class of compounds having a monocyclic core whose substituent moieties are selected and orientated by the monocyclic core to interact with and bind to CRTH2. The class of compounds with which this invention is concerned are thus capable of modulating CRTH2 activity, and are useful in the treatment of diseases which benefit from such modulation, for example asthma, allergy and rhinitis.

According to the present invention, there is provided the use of a compound of formula (I) or a salt, hydrate or solvate thereof in the manufacture of a composition for the treatment of disease responsive to modulation of CRTH2 receptor activity:



wherein

A represents a carboxyl group -COOH , or a carboxyl bioisostere;


A₁ is hydrogen or methyl;

ring Ar¹ is an optionally substituted phenyl ring or 5- or 6-membered monocyclic heteroaryl ring, in which $\text{AA}_1\text{CHO-}$ and **L2** are linked to adjacent ring atoms;

rings Ar², Ar³ each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted;

t is 0 or 1;

L2 and L3 each independently represents a divalent radical of formula



m, n and p are independently 0 or 1,

Alk¹ and Alk² are independently optionally substituted straight or branched chain C₁-C₃ alkylene or C₂-C₃ alkenylene radicals which may contain a compatible -O-, -S- or -NR- link wherein R is hydrogen or C₁-C₃ alkyl, and

Z is -O-, -S-, -C(=O)-, -SO₂-, -SO-, -NR-, -NRSO₂-, -SO₂NR-, -C(=O)NR-, -NRC(=O)-, -NRCONH-, -NHCONR-, -NRC(=NR)NH-, -NHC(=NR)NR-, -C(R)=N-NR-, or -NR-N=C(R)- wherein R is hydrogen or C₁-C₃ alkyl; or a divalent 5- or 6-membered monocyclic carbocyclic or heterocyclic radical,

PROVIDED THAT

- (A) the total length of L2 and L3 does not exceed that of an unbranched saturated chain of 10 carbon atoms; and
- (B) L2 is not -C(=O)-, -C(=O)NR-, or -NRC(=O)- when Ar² is optionally substituted phenyl; and
- (C) (a) L2 is not a bond and (b) p in L2 is not 0 when n is 1 and Z is aryl or heteroaryl, and
- (D) (a) L2 is not -O-, -SO₂-, -NR-, -CHR^XR^Y- or -CH(R^X)(OR^Y)-, wherein R^X and R^Y are independently hydrogen, halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, or C₃-C₇ cycloalkyl, or join to form a ring, and (b) when p is 1 and n is 1 and Z is aryl or heteroaryl then Alk² is not -CHR^XR^Y- or -CH(R^X)(OR^Y)-, wherein R^X and R^Y are independently hydrogen, halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, or C₃-C₇ cycloalkyl, or join to form a ring.

In one aspect of the invention, in compounds (I), the length of each of L2 and L3 does not exceed that of an unbranched saturated chain of 5 carbon atoms and (ii) the total length of L2 and L3 does not exceed that of an unbranched saturated chain of 7 carbon atoms, and (iii) neither of L2 and L3 includes more than two R substituents different from hydrogen.

In a narrower aspect of the invention, compounds (I) as defined above wherein A_1 is hydrogen and Z is $-O-$; $-S-$; $-C(=O)-$; $-SO_2-$; $-SO-$; $-NR-$, $-NRSO_2-$, $-C(=O)NR-$, $-NRCONH-$, $-NRC(=NR)NH-$, or $-C(R)=N-NR-$, wherein R is hydrogen or C_1 - C_3 alkyl; or a divalent 5- or 6-membered monocyclic carbocyclic or heterocyclic radical, may be used

In another narrower aspect of the invention, compounds (I) as defined above wherein L2 is $-N=CR-$, $-OCR_2C(=O)NR-N=CR-$, $-C(=O)NR-$, $-N=CR-$, $-C(=O)-$, $-CH=CHC(=O)-$, $-(CH_2)_{0-3}NRC(=O)-$, $-NRC(=O)(CH_2)_{0-3}-$, $-O-N=CH-$, $-CH_2NRCH_2-$, $-NR(CH_2)_{1-3}-$, $-(CH_2)_{1-3}NR-$, $-S-$, $-CH_2OCH_2-$, $-O(CH_2)_{1-3}-$, $-(CH_2)_{1-3}O-$, $-CH_2SCH_2-$, $-S(CH_2)_{0-3}-$, $-(CH_2)_{0-3}S-$, a divalent (C_2 - C_6)alkylene radical, a divalent (C_2 - C_6)alkenylene radical, or a divalent (C_2 - C_6)alkynylene radical, wherein R is hydrogen or C_1 - C_3 alkyl, may be used

In further narrower aspects of the invention, compounds (I) as defined above wherein L2 is $-NRN=CH-$, $-ON=CH-$, or $-N=CH-$; or L2 is $-C(=O)-$; or L2 is $-NHC(=O)-$ or $-C(=O)NH-$, may be used.

An independent aspect of the invention is the use of a compound of formula (I) set out above or a salt, hydrate or solvate thereof in the manufacture of a composition for the treatment of disease responsive to modulation of CRTH2 receptor activity, in which compound (I):

A represents a carboxyl group $-COOH$, or a carboxyl bioisostere;

A₁ is hydrogen or methyl;

ring Ar¹ is an optionally substituted phenyl ring or 5- or 6-membered monocyclic heteroaryl ring, in which AA_1CHO- and L2 are linked to adjacent ring atoms;

rings Ar², Ar³ each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted;

t is 0 or 1;


L3 represents a divalent radical of formula $-(\text{Alk}^1)_m-(\text{Z})_n-(\text{Alk}^2)_p$ wherein

m, n and p are independently 0 or 1,

Alk¹ and Alk² are independently optionally substituted straight or branched chain C₁-C₃ alkylene or C₂-C₃ alkenylene radicals which may contain a compatible -O-, -S- or -NR- link wherein R is hydrogen or C₁-C₃ alkyl, and

Z is -O-; -S-; -C(=O)-; -SO₂-; -SO-; -NR-, -NRSO₂-, -SO₂NR-,
-C(=O)NR-, -NRC(=O)-, -NRCONH-, -NHCONR-, -NRC(=NR)NH-,
-NHC(=NR)NR-, -C(R)=N-NR-, or -NR-N=C(R)- wherein R is hydrogen or
C₁-C₃ alkyl; or a divalent 5- or 6-membered monocyclic carbocyclic or
heterocyclic radical;

L2 represents a divalent radical selected from one of the following formulae (sometimes called “L2 set A” herein), wherein either (i) the bond marked * is attached to Ar² while the bond marked ** is attached to Ar¹, or (ii) the bond marked * is attached to Ar¹ while the bond marked ** is attached to Ar²:




wherein R is hydrogen or C₁-C₃ alkyl; and

the total length of L2 and L3 does not exceed that of an unbranched saturated chain of 10 carbon atoms.

In a narrower definition of this aspect of the invention, in the compounds (I), (i) the length of L3 does not exceed that of an unbranched saturated chain of 5 carbon atoms and (ii) the total length of L2 and L3 does not exceed that of an unbranched saturated chain of 7 carbon atoms, and (iii) L3 does not include more than two R substituents different from hydrogen.

In the two immediately foregoing aspects of the invention, in the compounds (I), A1 may be hydrogen and L2 may be one of the following formulae (sometimes called "L2 set B" herein) wherein the bond marked * is attached to Ar² while the bond marked ** is attached to Ar¹:



wherein R is hydrogen or C₁-C₃ alkyl.

The compounds with which the invention is concerned are defined by reference to formula (I) as a result of studies towards elucidation of the ligand binding site of

CRT2. Such studies led to the overall conclusion that a general pharmacophore comprising one negatively charged moiety, represented by AA_1CHO^- , and two aromatic and/or hydrophobic moieties, represented by Ar^2L_2 and either $H(Ar^3)_1L_3-Ar^1$ or only Ar^1 , oriented in an approximate triangle, would form an arrangement for interaction with the receptor binding site. It was concluded that the substituent groupings AA_1CHO^- and Ar^2L_2 should be on adjacent ring atoms of Ar^1 . The linkers L_2 and L_3 provide some flexibility to the molecule to facilitate optimum binding. The restrictions on the lengths of, and substitutions in, the linkers L_2 and L_3 are in order to restrict the total molecular size and complexity of structures for use in accordance with the invention. For the avoidance of doubt, the total length of L_2 and L_3 is, for the purposes of this description and claims, the sum n_2+n_3 , where n_2 is the number of connected atoms in the shortest chain of atoms from terminal atom to terminal atom of linker L_2 , and n_3 is the number of connected atoms in the shortest chain of atoms from terminal atom to terminal atom of linker L_3 . Preferably the compounds with which the invention is concerned should have a molecular weight of no more than 600. Optional substituents in any element of the compounds (I) are permitted as in the definition of compounds (I). Such substituents can modulate pharmacokinetic and solubility properties, as well as picking up additional binding interactions with the receptor.

In another aspect, the invention provides a method of treatment of a subject suffering from a disease responsive to modulation of CRT2 receptor activity, which comprised administering to the subject an amount of a compound (I) as defined and described above effective to ameliorate the disease.

In particular, compounds with which the invention is concerned are useful in the treatment of disease associated with elevated levels of prostaglandin D2 (PGD2) or one or more active metabolites thereof.

Examples of such diseases include asthma, rhinitis, allergic airway syndrome, allergic rhinobronchitis, bronchitis, chronic obstructive pulmonary disease (COPD), nasal polyposis, sarcoidosis, farmer's lung, fibroid lung, cystic fibrosis, chronic cough, conjunctivitis, atopic dermatitis, Alzheimer's disease, amyotrophic lateral sclerosis, AIDS dementia complex, Huntington's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, Guillain-Barre syndrome, chronic demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathy, multiple sclerosis, encephalomyelitis, panencephalitis, cerebellar degeneration and

encephalomyelitis, CNS trauma, migraine, stroke, rheumatoid arthritis, ankylosing spondylitis, Behçet's Disease, bursitis, carpal tunnel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, dermatomyositis, Ehlers-Danlos Syndrome (EDS), fibromyalgia, myofascial pain, osteoarthritis (OA), osteonecrosis, psoriatic arthritis, Reiter's syndrome (reactive arthritis), sarcoidosis, scleroderma, Sjogren's Syndrome, soft tissue disease, Still's Disease, tendinitis, polyarteritis Nodosa, Wegener's Granulomatosis, myositis (polymyositis dermatomyositis), gout, atherosclerosis, lupus erythematosus, systemic lupus erythematosus (SLE), type I diabetes, nephritic syndrome, glomerulonephritis, acute and chronic renal failure, eosinophilia fascitis, hyper IgE syndrome, sepsis, septic shock, ischemic reperfusion injury in the heart, allograft rejection after transplantations, and graft versus host disease.

However, the compounds with which the invention is concerned are primarily of value for the treatment asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.

Many compounds of formula (I) above are novel in their own right, and the invention includes such novel compounds *per se*.

As used herein, the term "(C_a-C_b)alkyl" wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms. Thus when a is 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.

As used herein the term "divalent (C_a-C_b)alkylene radical" wherein a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valences.

As used herein the term "(C_a-C_b)alkenyl" wherein a and b are integers refers to a straight or branched chain alkenyl moiety having from a to b carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. The term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl.

As used herein the term "divalent (C_a-C_b)alkenylene radical" means a hydrocarbon chain having from a to a carbon atoms, at least one double bond, and two unsatisfied valences.

As used herein the term " C_a-C_b alkynyl" wherein a and b are integers refers to straight chain or branched chain hydrocarbon groups having from two to six carbon atoms and having in addition one triple bond. This term would include for example, ethynyl, 1- and 2-propynyl, 1-, 2- and 3-butynyl, 1, 2-, 3- and 4-pentynyl, 1-, 2-, 3-, 4- and 5-hexynyl, 3-methyl-1-butynyl, 1-methyl-2-pentynyl.

As used herein the term "divalent (C_a-C_b)alkynylene radical" wherein a and b are integers refers to a divalent hydrocarbon chain having from 2 to 6 carbon atoms, at least one triple bond, and two unsatisfied valences.

As used herein the term "carbocyclic" refers to a mono-, bi- or tricyclic radical having up to 16 ring atoms, all of which are carbon, and includes aryl and cycloalkyl.

As used herein the term "cycloalkyl" refers to a monocyclic saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.


As used herein the unqualified term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical, and includes radicals having two monocyclic carbocyclic aromatic rings which are directly linked by a covalent bond. Illustrative of such radicals are phenyl, biphenyl and naphthyl.

As used herein the unqualified term "heteroaryl" refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O, and includes radicals having two such monocyclic rings, or one such monocyclic ring and one monocyclic aryl ring, which are directly linked by a covalent bond. Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyridazinyl, triazinyl, indolyl and indazolyl.

As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in addition means a mono-, bi- or tri-cyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more

such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical. Illustrative of such radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.

The term "carboxyl bioisostere" is a term familiar to medicinal chemists (see for example "The Organic Chemistry of Drug Design and Drug Action", by Richard B. Silverman, pub. Academic Press, 1992), and refers to a group which has similar acid-base characteristics to those of a carboxyl group. Well known carboxyl bioisosteres include $-\text{SO}_2\text{NHR}$ or $-\text{P}(=\text{O})(\text{OH})(\text{OR})$ wherein R is, for example, hydrogen methyl or ethyl, $-\text{SO}_2\text{OH}$, $-\text{P}(=\text{O})(\text{OH})(\text{NH}_2)$, $-\text{C}(=\text{O})\text{NHCN}$ and groups of formulae:



Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, hydroxy, hydroxy $(\text{C}_1\text{-C}_6)\text{alkyl}$, mercapto, mercapto $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkylthio}$, halo (including fluoro, bromo and chloro), fully or partially fluorinated $(\text{C}_1\text{-C}_3)\text{alkyl}$, $(\text{C}_1\text{-C}_3)\text{alkoxy}$ or $(\text{C}_1\text{-C}_3)\text{alkylthio}$ such as trifluoromethyl, trifluoromethoxy, and trifluoromethylthio, nitro, nitrile $(-\text{CN})$, oxo, phenyl, phenoxy, $-\text{COOR}^A$, $-\text{COR}^A$, $-\text{OCOR}^A$, $-\text{SO}_2\text{R}^A$, $-\text{CONR}^A\text{R}^B$, $-\text{SO}_2\text{NR}^A\text{R}^B$, $-\text{NR}^A\text{R}^B$, $-\text{OCONR}^A\text{R}^B$, $-\text{NR}^B\text{COR}^A$, $-\text{NR}^B\text{COOR}^A$, $-\text{NR}^B\text{SO}_2\text{OR}^A$ or $-\text{NR}^A\text{CONR}^A\text{R}^B$ wherein R^A and R^B are independently hydrogen or a $(\text{C}_1\text{-C}_6)\text{alkyl}$ group or, in the case where R^A and R^B are linked to the same N atom, R^A and R^B taken together with that nitrogen may form a cyclic amino ring. Where the substituent is phenyl or phenoxy, the phenyl ring thereof may itself be substituted by any of the above substituents except phenyl or phenoxy. An "optional substituent" may be one of the foregoing substituent groups.

As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g.

sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like. Those compounds (I) which are basic can form salts, including pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesulphonic, glutamic, lactic, and mandelic acids and the like.

Compounds with which the invention is concerned which may exist in one or more stereoisomeric form, because of the presence of asymmetric atoms or rotational restrictions, can exist as a number of stereoisomers with R or S stereochemistry at each chiral centre or as atropisomers with R or S stereochemistry at each chiral axis. The invention includes all such enantiomers and diastereoisomers and mixtures thereof.

Use of prodrugs, such as esters, of compounds (I) with which the invention is concerned is also part of the invention.

For use in accordance with the above aspects of the invention the following structural characteristics may be present, in any compatible combination, in the compounds (I):

L2 may be a member of L2 set A above (and of course L2 set A includes L2 set B);

L2 may be -N=CR-, -OCR₂C(=O)NR-N=CR-, -C(=O)NR-, -N=CR-, -C(=O)-, -CH=CHC(=O)-(CH₂)₀₋₃NRC(=O)-, -NRC(=O)(CH₂)₀₋₃-, -O-N=CH-, -CH₂NRCH₂-, -NR(CH₂)₁₋₃-, -(CH₂)₁₋₃NR-, -S-, -CH₂OCH₂-, -O(CH₂)₁₋₃-, -(CH₂)₁₋₃O-, -CH₂SCH₂-, -S(CH₂)₀₋₃-, -(CH₂)₀₋₃S-, a divalent (C₂-C₆)alkylene radical, a divalent (C₂-C₆)alkenylene radical, or a divalent (C₂-C₆)alkynylene radical, wherein R is hydrogen or C₁-C₃ alkyl;

L2 may be -NRN=CH-, -ON=CH-, -N=CH-, -C(=O)-, -NHC(=O)- or -C(=O)NH-;

Ar² may be an optionally substituted phenyl or 5- or 6-membered nitrogen-containing heteroaryl ring, for example pyridyl, pyrimidyl, diazolyl, thiazolyl, oxazolyl, triazinyl, quinoliny, pyrrollyl, furanyl, thiazolyl;

Optional substituents in Ar² may be selected from fluoro, chloro, bromo, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₃alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, and nitro;

Ar¹ may be an optionally substituted 5- or 6-membered nitrogen-containing heteroaryl ring, for example pyridyl, pyrimidyl, diazolyl, thiazolyl, oxazolyl, triazinyl, quinoliny, pyrrollyl, furanyl, thiazolyl, and wherein L3 may be linked to a ring carbon in (for a 6-membered ring) the 4 position thereof relative to the ACHA₁O- radical or (for a 5-membered ring) the 4 position thereof counting the ACHA₁O- radical as in position 1 and the Ar²L₂- radical as in position 2 thereof;


Ar¹ may be an optionally substituted phenyl ring wherein L3 is linked to the 4 position thereof relative to the ACHA₁O- radical;

when t is 1, Ar³ may be an optionally substituted phenyl ring, or an optionally substituted 5- or 6-membered heteroaryl ring, for example pyridyl, pyrimidyl, diazolyl, thiazolyl, oxazolyl, triazinyl, quinoliny, pyrrollyl, furanyl, or thiazolyl;

optional substituents in ring Ar¹ or Ar³ may be selected from fluoro, chloro, bromo, iodo, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, (C₁-C₃alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, C₁-C₆ alkyl, C₁-C₆ alkoxy, cycloalkyl, aryl, aryloxy, aryl(C₁-C₆)- or aryl(C₁-C₆ alkoxy)-;

when t is 0, L3 may be a bond;


A may be -COOH or a carboxyl bioisostere selected from -SO₂NHR and -P(=O)(OH)(OR) wherein R is hydrogen methyl or ethyl, -SO₂OH, -P(=O)(OH)(NH₂), -C(=O)NHCN and groups of formulae:



It is currently preferred that A be carboxyl;

A₁ may be hydrogen or methyl.


Compounds (I) for use in accordance with the invention include those of formula (IV) and salts, hydrates or solvates thereof, which are believed novel *per se*, and which form another aspect of the invention:



wherein A, A₁, L₃, Ar³, Ar², and t are as defined and discussed above in relation to formula (I), R₁₃ represents hydrogen or one or more optional substituents, and L₂ is a member of the L₂ set A, as defined above. This includes the case where A₁ is hydrogen and L₂ is a member of the L₂ set B as defined above.

The following structural characteristics may be present in compounds (IV), in any compatible combination:

A may be -COOH, or a carboxyl bioisostere selected from -SO₂NHR and -P(=O)(OH)(OR) wherein R is hydrogen methyl or ethyl, -SO₂OH, -P(=O)(OH)(NH₂), -C(=O)NHCN and groups of formulae:




Currently it is preferred that A be carboxyl.

R_{13} may represent one or more substituents selected from fluoro, chloro, bromo, iodo, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, $(C_1-C_3\text{alkyl})SO_2-$, NH_2SO_2- , $(C_1-C_3\text{alkyl})NHSO_2-$, $(C_1-C_3\text{alkyl})_2NSO_2-$, C_1-C_6 alkyl, C_1-C_6 alkoxy, cycloalkyl, aryl, aryloxy, aryl(C_1-C_6)- or aryl(C_1-C_6 alkoxy)-.


A_1 may be methyl or A_1 may be hydrogen.

One preferred subset of the compounds (IV) has formula (IVA)




wherein A, A_1 , L_3 , t, Ar^3 , R_{13} are as defined and discussed above in relation to compounds of formula (I) and (IV) and R_{14} is optionally substituted phenyl or 5- or 6-membered heteroaryl.

Another preferred subset of the compounds (IV) has formula (IVB):



wherein A_1 , L_3 , t, and Ar^3 are as defined and discussed above in relation to formulae (I), (IV) and (IVA), and R_{14} is optionally substituted phenyl or 5- or 6-membered heteroaryl

Another preferred subset of the compounds (IV) has formula (IVC):



wherein R_{13} represents a substituent selected from fluoro, chloro, bromo, iodo, (C_1-C_6) alkyl, trifluoromethyl, (C_1-C_6) alkoxy, (C_1-C_6) alkylmercapto, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C_1-C_3) alkyl SO_2^- , $NH_2SO_2^-$, (C_1-C_3) alkyl $NHSO_2^-$, (C_1-C_3) alkyl $_2NSO_2^-$, and nitro, and R_{14} is optionally substituted phenyl or 5- or 6- membered heteroaryl. In this subset, R_{14} may be a 2-substituted, 2,4-disubstituted, 2,6-disubstituted or 2,4,6-trisubstituted phenyl ring where the substituents are selected from fluoro, chloro, bromo, iodo, (C_1-C_6) alkyl, trifluoromethyl, (C_1-C_6) alkoxy, (C_1-C_6) alkylmercapto, trifluoromethoxy, trifluoromethylthio, dimethylamino, (C_1-C_3) alkyl SO_2^- , $NH_2SO_2^-$, (C_1-C_3) alkyl $NHSO_2^-$, (C_1-C_3) alkyl $_2NSO_2^-$, and cyano. This subset specifically includes compounds wherein A_1 is hydrogen.

In any compound (I), (IV) (IVA), (IVB) or IVC) defined and discussed above, wherein A_1 is methyl, the carbon atom to which it is attached preferably has the S stereochemical configuration.

Specific novel compounds of the invention are the following:

4-chloro-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetic acid,
 4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetic acid,
 [4-bromo-2-(1-pyridin-2-yl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid,
 {4-bromo-2-[1-(2-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
 {4-bromo-2-[1-(3-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
 {4-bromo-2-[1-(4-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
 {4-bromo-2-[1-(4-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
 {4-bromo-2-[1-(2-ethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
 {4-bromo-2-[1-(2-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
 {4-bromo-2-[1-(2-fluorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
 {4-bromo-2-[1-(2-trifluoromethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,

{4-bromo-2-[1-(3-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(2,4-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{2-[1-(2-chlorophenyl)-1H-pyrazole-4-carbonyl]-4-nitrophenoxy}acetic acid,
{4-bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{2-[1-(2-bromophenyl)-1H-pyrazole-4-carbonyl]-4-ethylphenoxy}acetic acid,
{4-bromo-2-[1-(2,4-dibromophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(4-bromo-2-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
2-[4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]propionic acid,
(S)-2-[4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]propionic acid,
2-{4-Bromo-2-[1-(2-chlorophenyl)-1-H-pyrazole-4-carbonyl]phenoxy}propionic acid,
(S)-2-{4-Bromo-2-[1-(2-chlorophenyl)-1-H-pyrazole-4-carbonyl]phenoxy}propionic acid,
2-{4-Bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid,
(S)-2-{4-Bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid,
{4-Bromo-2-[1-(2-ethoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(4-bromo-2-ethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2-phenoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2-methylthiophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2-bromo-4-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
2-{4-Bromo-2-[1-(4-bromo-2-ethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid,
2-{4-Bromo-2-[1-(2-phenoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid,
(S)-2-{4-Bromo-2-[1-(2-phenoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid,
2-{4-Bromo-2-[1-(2-methylthio)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid,
(S)-2-{4-Bromo-2-[1-(2-methylthio)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid,
{4-Bromo-2-[1-(2,4-dimethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(4-chloro-2-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2,5-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
2-{4-Bromo-2-[1-(4-chloro-2-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid,

2-{4-Bromo-2-[1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid,
{4-Bromo-2-[1-(2,6-diethyl-phenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2,6-dimethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid
{4-Bromo-2-[1-(2-ethyl-6-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2-chloro-6-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(3,5-dichloropyridin-4-yl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
[4-Bromo-2-(1-naphthalen-1-yl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid,
{4-Bromo-2-[2-(4-chlorobenzyl)thiazol-4-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(4-fluoro-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid,
{4-Bromo-2-[3-(2,6-dichloro-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid,
{4-Bromo-2-[3-(2-trifluoromethylbenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}-acetic acid,
4-Bromo-2-[3-(2,6-dichloro-phenyl)isoxazole-5-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[3-(1-phenylcyclopropyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(2,4-dichlorophenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,

and salts, hydrates and solvates thereof.

The invention also includes pharmaceutical compositions comprising a compound belonging to the above described compounds of formula (IV), (IVA), (IVB) or (IVC), together with a pharmaceutically acceptable carrier.

Compositions

As mentioned above, the compounds with which the invention is concerned are capable of modulating CRTH2 activity, and are useful in the treatment of diseases which benefit from such modulation. Examples of such diseases are referred to above, and include asthma, allergy and rhinitis.

It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular

disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial, as is required in the pharmaceutical art.

The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.

For topical application to the eye, the drug may be made up into a solution or suspension in a suitable sterile aqueous or non aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite or disodium edeate; preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.

The drug may also be formulated for inhalation, for example as a nasal spray, or dry powder or aerosol inhalers.

The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.

The compounds with which the invention is concerned may be administered alone, or as part of a combination therapy with other drugs used for treatment of diseases with a major inflammatory component. In the case of asthma, rhinitis, and allergic airway syndrome such drugs include corticosteroids, long-acting inhaled beta agonists, cromolyn, nedocromil, theophylline, leukotriene receptor antagonists, antihistamines, and anticholinergics (e.g. ipratropium), and are often administered as nasal sprays, dry powder or aerosol inhalers.


In the case of arthritis and related inflammatory diseases other known drugs include glucocorticoids, NSAIDs (Non Steroidal Anti-Inflammatory Drugs – conventional prostaglandin synthesis inhibitors, COX-2 inhibitors, salicylates), and DMARDs (disease-modifying anti-rheumatic drugs such as methotrexate, sulfasalazine, gold, cyclosporine).

Synthetic Routes


There are multiple synthetic strategies for the synthesis of the compounds (I) with which the present invention is concerned, but all rely on known chemistry, known to the synthetic organic chemist. Thus, compounds according to Formula I can be synthesised according to procedures described in the standard literature and are well-known to the one skilled in the art. Typical literature sources are “*Advanced organic chemistry*”, 4th Edition (Wiley), J March, “*Comprehensive Organic Transformation*”, 2nd Edition (Wiley), R.C. Larock, “*Handbook of Heterocyclic Chemistry*”, 2nd Edition (Pergamon), A.R. Katritzky), review articles such as found in “*Synthesis*”, “*Acc. Chem. Res.*”, “*Chem. Rev*”, or primary literature sources identified by standard literature searches online or from secondary sources such as “*Chemical Abstracts*” or “*Beilstein*”.

In the discussion which follows, A represents a carboxylic acid, a carboxyl bioisostere, or a protected carboxylic acid or bioisostere, or a precursor of these. In the latter case, a deprotection step is implied. A₁ represents hydrogen or methyl.

Many compounds claimed in this invention may be synthesized by reacting a phenol precursor with LG-CH(A₁)-A, where LG is a leaving group and A is a carboxylic acid or a protected analog or precursor, or a bioisostere or a protected analog of this.



The linker L2 can be formed by joining two appropriately functionalised and, if needed, suitably protected fragments containing La2 and Lb2 as reactive moieties as outlined below. La2 and Lb2 are defined as any moieties that can react by e.g. a nucleophilic substitution, addition to multiple bonds or cyclisation reaction to form a given L2 linker as exemplified below.



For example, the linker -L2- being -Alk¹-Z-(Alk²)_p- can be formed by reacting Ar²-Alk¹-“leaving group” with a nucleophilic derivative H-Z-(Alk²)_p-Ar¹(L1A)L3Ar³H wherein Z could be O, S or NR and Alk¹ could be an alkyl group. The reactions can also be made by reversing the functionalisation of La2 and Lb2 to make the connection between Z and Alk². The linkers wherein Z is SO or SO₂ can be obtained by oxidations of the corresponding -(Alk¹)_m-S-(Alk²)_p- derivatives during appropriate conditions.


Further representative examples, -L2- being -Alk¹-Z-(Alk²)_p- wherein Z is NH(CO) or NHSO₂ can be formed by reacting Ar²-(Alk¹)-NH₂ with an acylating derivative “leaving group”-CO-(Alk²)_p-Ar¹(L1A)L3Ar³H or “leaving group”-SO₂-(Alk²)_p-Ar¹(L1A)L3Ar³H, respectively. Alternatively, the conversion can be made directly with the acids HO-

CO-(Alk²)_p-Ar¹(L1A)L3Ar³H and HO-SO₂-(Alk²)_p-Ar¹(L1A)L3Ar³H, respectively, using suitable coupling reagents such as dicyclohexylcarbodiimide (DCC), and promoters such as 1-hydroxybenzotriazole. Analogously, -L2- being -Alk¹-Z-(Alk²)_p- wherein Z being NH(CO)NH can be formed by reacting Ar²-(Alk¹)-NH₂ with an isocyanate derivative OCN-(Alk²)_p-Ar¹(L1A)L3Ar³H using suitable acid or base catalysis. The reactions can also be made by reversing the functionalisation of La2 and Lb2 to provide the "retro-bonds" in the case of NH(CO) or NHSO₂. Analogously, the connections can be made between Z and Alk².

A metal catalyzed coupling reaction like the Stille coupling reaction, the Suzuki coupling reaction, the Heck reaction and the Sonogashira reaction are useful in the synthesis of examples with L2 being an divalent alkylene radical, a divalent alkenylene radical or a divalent alkynylene radical.


Compounds with L2 being a hydrazone are usually conveniently formed by a condensation reaction between the corresponding hydrazines and aldehydes in ethanol or without solvent.

Likewise, L2 being -(Alk¹)_m-Z-(Alk²)_p- wherein Z is a 5-membered heterocyclic system exemplified by, for example,




can be made according to standard cyclisation procedures using appropriate solvents, catalysts and temperatures. For example, formation of 1,2,4-triazole can be made with La2 being acylhydrazide and Lb2 being amide or thioamide or the reverse orientation of La2 and Lb2. 1,2,4-Oxadiazole can be formed from La2 being amidoxime and Lb2 being carboxylic ester or the reverse orientation of La2 and Lb2. 1,3,4-Oxadiazole can be formed from La2 being acylhydrazide and Lb2 being carboxylic ester or the reverse orientation of La2 and Lb2. The thiazole can be made from La2 being thioamide and Lb2 being an α -haloketone or the reverse orientation of La2 and Lb2. The isoxazole can be made from La2 being alkyne and Lb2 being nitroxide or the reverse orientation in a cycloaddition reaction.

In an analogous manner the compounds of formula I can be made by forming the linker L3, according to procedures outlined for L2, as depicted below. Thus, La and Lb are defined as any moieties that can react by e.g. a nucleophilic substitution, addition to multiple bonds or cyclisation reaction to form a given linker as exemplified below.




The Ar¹ moiety can also be the central scaffold that is used in connecting the L2 and L3 parts in a stepwise fashion. This can be done via aromatic substitutions of the Ar¹ core to attach L2 and/or L3, which then can be further functionalised to give the final Formula I compounds.

Furthermore, the Ar¹ moiety can also be assembled via ring cyclisation reactions with reactants containing the L2 and L3 units either containing the full appendices as outlined below:



or in forms that can be further functionalised into the final Formula I structures as described previously. One such illustration is given below



For example, 1,2,4-triazoles can be made from acylhydrazides and amides or thioamides; 1,2,4-Oxadiazoles from amidoximes and carboxylic esters; 1,3,4-Oxadiazoles from acylhydrazides and carboxylic esters; Thiazoles from thioamides and α -haloketones; Pyridines via various cycloaddition reactions.

The building blocks used in the reactions are either commercially available or made according to standard procedures well-known to one skilled in the art as described in "Advanced organic chemistry", 4th Edition (Wiley), J March, "Comprehensive Organic Transformation", 2nd Edition (Wiley), R.C. Larock, "Handbook of Heterocyclic Chemistry", 2nd Edition (Pergamon), A.R. Katritzky or other suitable literature sources. The Examples herein describe specific strategies for the synthesis of compounds wherein Ar¹ is phenyl. Analogous compounds are accessible by variation of the intermediates used in the Examples.


The following Examples illustrate the preparation of compounds with which this invention is concerned. Some compounds were synthesised, and some were acquired from commercial sources. In the Examples:

General comments:


Microwave chemistry was performed in a Personal Chemistry Emrys Optimizer. NMR spectra were obtained on a Bruker Avance AMX 300 MHz instrument. LC/MS was performed on an Agilent 1100-series instrument. LC/MS methods are as follows:

An10p8: Column: XTerra MS C18; Flow: 1.0 mL/min; Gradient: 0-5 min: 15-100% MeCN in water, 5-7½ min: 100% MeCN; Modifier: 5 mM ammonium formate; MS-ionisation mode: API-ES (pos.). An10n8: Column: XTerra MS C18; Flow: 1.0 mL/min; Gradient: 0-5 min: 15-100% MeCN in water, 5-7½ min: 100% MeCN; Modifier: 5 mM ammonium formate; MS-ionisation mode: API-ES (neg.).

General synthetic route I



General synthetic route II



General procedure 1 (GP1):

Condensation of 3-formylchromone with arylhydrazine

The 3-formylchromone (1.0 mmol) and the arylhydrazine (1.0 mmol) in ethanol (3.0 mL) in a reaction tube was added 4.0 M aq. KOH (1.0 mL, 4.0 mmol). The tube was sealed and heated by microwaves to 120 °C for 7 min (420 s). The reaction mixture was added 3% HCl until pH <1 and left to precipitated. The precipitate was filtered off and washed with a small amount of ethanol. The product was used directly or purified by recrystallisation from ethanol or by flash chromatography.

General procedure 2 (GP2):

Alkylation of phenol

The phenol (0.5 mmol) in acetone (1 mL) was added ethyl bromoacetate (85 mg, 0.5 mmol) or ethyl 2-bromopropionate (91 mg, 0.5 mmol) and K_2CO_3 (75 mg, 0.54 mmol), and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was then concentrated in vacuo and the residue was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried ($MgSO_4$) and concentrated. The product was used directly or purified by recrystallization from MeOH or by flash chromatography.

General procedure 3 (GP3):


Hydrolysis of ester

The ester (0.10 mmol) in THF (0.5 mL) was added $LiOH \cdot H_2O$ (6.3 mg, 0.15 mmol) in water (0.5 mL). The reaction was stirred at room temperature for >2 h, 3% HCl was added until pH <1, and the mixture was extracted with CH_2Cl_2 . The organic phase was dried ($MgSO_4$) and concentrated to give the product.

General procedure 4 (GP4):

Suzuki coupling/ester hydrolysis


Aryl bromide (0.20 mmol), aryl boronic acid (0.21 mmol) and $Pd(PPh_3)_2Cl_2$ (9 mg, 0.01 mmol) was added MeCN (0.4 mL, degassed) and 1.0 M Na_2CO_3 (0.4 mL, degassed). The reaction mixture was degassed by letting argon through for ½ min and heated by microwaves (150 °C, 300 s), then added 3% HCl until pH <1 and extracted with CH_2Cl_2 . The extract was filtered through celite and concentrated, and the residue was purified by solid-phase extraction (pre-packed 1 g SAX columns), or by flash chromatography.




Intermediate-1

Ethyl 4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetate. Prepared from (5-bromo-2-hydroxy-phenyl)-(1-phenyl-1H-pyrazol-4-yl)ketone and ethyl bromoacetate according to GP2 to give 215 mg (100%) white crystals. The product was used without further purification: LC/MS (an10p8): Rt 6.15 min, m/z 429 [$M + H$]⁺; 1H NMR ($CDCl_3$): δ 1.26 (t, $J = 7.1$ Hz, 3H), 4.24 (q, $J = 7.1$ Hz, 2H), 4.64 (s, 2H), 6.72 (d, $J = 8.9$ Hz, 1H), 7.34 (m, 1H), 7.46 (m, 2H), 7.53 (dd, $J = 8.9, 2.5$ Hz, 1H),

7.59 (d, $J = 2.5$ Hz, 1H), 7.73-7.78 (m, 2H), 8.17 (s, 1H), 8.58 (s, 1H); ^{13}C NMR (CDCl_3): δ 14.3, 61.9, 65.5, 114.0, 114.5, 119.8, 125.3, 127.7, 129.8, 131.8, 132.3, 132.7, 134.6, 139.6, 142.7, 154.1, 168.5, 186.9.




4-Bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetic acid. Prepared from ethyl 4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetate (31 mg, 0.072 mmol) according to GP3 to give 28.4 mg (99%) white solid: LC/MS (an10p8): Rt 3.14 min, m/z 401; ^1H NMR (CDCl_3): δ 3.51 (s, 1H), 4.80 (s, 1H), 6.97 (d, $J = 8.7$ Hz, 1H), 7.38-7.44 (m, 1H), 7.49-7.55 (m, 2H), 7.64-7.69 (m, 1H), 7.72-7.77 (m, 3H), 8.19 (s, 1H), 8.52 (s, 1H); ^{13}C NMR (CDCl_3): δ 67.2, 115.1, 116.6, 120.1, 124.5, 128.4, 130.0, 131.9, 133.3, 136.2, 139.2, 143.3, 155.2, 169.9, 187.6.




Intermediate-2

Ethyl 2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetate. Prepared from (2-hydroxyphenyl)-(1-phenyl-1H-pyrazol-4-yl)ketone (264 mg, 1.0 mmol) and ethyl bromoacetate according to GP2 to give 235 mg (67%) of the title compound as white solid: ^1H NMR (CDCl_3): δ 1.26 (t, $J = 7.1$ Hz, 3H), 4.24 (q, $J = 7.1$ Hz, 2H), 4.67 (s, 2H), 6.84 (d, $J = 8.3$ Hz, 1H), 7.10 (ts, $J = 7.4, 0.8$ Hz, 1H), 7.29-7.36 (m, 1H), 7.41-7.53 (m, 4H), 7.72-7.78 (m, 2H), 8.18 (s, 1H), 8.58 (s, 1H); ^{13}C NMR (CDCl_3): δ 14.3, 61.7, 65.4, 112.2, 118.8, 119.3, 119.7, 120.0, 122.1, 125.8, 127.6, 129.7, 129.9, 130.1, 130.6, 131.8, 132.1, 136.3, 139.7, 142.8, 155.0, 168.9, 188.7.




2-(1-Phenyl-1H-pyrazole-4-carbonyl)phenoxyacetic acid. Prepared from ethyl 2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetate according to GP3 and purified by column chromatography (SiO_2 , EtOAc:heptane, 1:1) to give 15 mg (56%) of the title

compound as white solid: LC/MS (an10n8): Rt 2.90 min, m/z 321.0 $[M-H]^-$; 1H NMR ($CDCl_3$): δ 4.83 (s, 2H), 7.10 (d, J = 8.3 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 7.35-7.42 (m, 1H), 7.46-7.53 (m, 2H), 7.54-7.61 (m, 1H), 7.66 (dd, J = 7.5, 1.5 Hz, 1H), 7.70-7.75 (m, 2H); ^{13}C NMR ($CDCl_3$): δ 67.7, 115.5, 120.1, 122.8, 124.7, 128.3, 128.6, 129.9, 131.0, 131.9, 134.0, 139.3, 143.5, 156.6, 170.4, 189.3.




Intermediate-3

Ethyl 4-fluoro-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetate. Prepared from 4-fluoro-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenol (282 mg) and ethyl bromoacetate according to GP2 to give 335 mg (91%) yellow solid: LC/MS (an10n8): Rt 3.16, m/z 339.0 $[M-H]^-$; 1H NMR ($CDCl_3$): δ 1.26 (t, J = 7.0 Hz, 3H), 4.23 (t, J = 7.1 Hz, 2H), 4.63 (s, 2H), 6.81 (dd, J = 9.0, 4.0 Hz, 1H), 7.13 (ddd, J = 8.9, 4.5, 3.0 Hz, 1H), 7.21 (dd, J = 8.1, 3.2 Hz, 1H), 7.31-7.37 (m, 1H), 7.24-7.50 (m, 2H), 7.72-7.78 (m, 2H), 8.18 (s, 1H), 8.58 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 14.3, 61.8, 66.1, 114.0 (d, J_{CF} = 7.6 Hz), 116.8 (d, J_{CF} = 24.5 Hz), 118.3 (d, J_{CF} = 23.5 Hz), 119.7, 125.2, 127.7, 129.7, 131.8, 139.6, 142.8, 151.1 (d, J_{CF} = 2.2 Hz), 157.6 (d, J_{CF} = 241.1 Hz), 168.7, 187.1.




D3


4-Fluoro-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetic acid. Prepared from ethyl 4-fluoro-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetate (31 mg) according to GP3 to give 30 mg (100%) of a pale yellow solid: LC/MS (an10n8): Rt 3.16, m/z 339.0 $[M-H]^-$; 1H NMR ($CDCl_3$): δ 4.60 (s, 2H), 6.90 (dd, J = 9.2 Hz, 1H), 7.08-7.17 (m, 1H), 7.21 (dd, J = 7.9, 3.0 Hz, 1H), 7.28-7.35 (m, 1H), 7.38-7.46 (m, 2H), 7.65 (d, J = 7.5 Hz, 2H), 8.06 (s, 1H), 8.44 (s, 1H).

**Intermediate-4**


4-Bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetonitrile. (5-Bromo-2-hydroxy-phenyl)-(1-phenyl-1H-pyrazol-4-yl)ketone (342 mg) was added bromoacetonitrile (122 mg), acetone (2 mL) and K_2CO_3 (140 mg), and the reaction was stirred for 24 h. The reaction mixture was concentrated and the residue was partitioned between water and EtOAc. The organic phase was washed with brine, dried ($MgSO_4$) and concentrated to give 383 mg (100%) yellow solid, that was used directly in the next step: LC/MS (an10p8): Rt 4.39 min, m/z 381.5 $[M + 1]^+$; 1H NMR ($CDCl_3$): δ 4.80 (s, 2H), 7.07 (d, $J = 8.7$ Hz, 1H), 7.35-7.42 (m, 1H), 7.45-7.54 (m, 2H), 7.60-7.69 (m, 2H), 7.69-7.75 (m, 2H), 8.03 (s, 1H), 8.31 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 55.2, 114.7, 116.6, 116.7, 120.1, 125.1, 128.2, 129.9, 131.0, 132.6, 133.2, 135.0, 139.3, 142.7, 153.0, 186.0.

**D4**

[5-Bromo-2-(2H-tetrazol-5-ylmethoxy)phenyl][(1-phenyl-1H-pyrazol-4-yl)ketone. [4-Bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]-acetonitrile (38 mg) was added NaN_3 (66 mg), $ZnBr_2$ (59 mg), isopropanol (1.3 mL) and water (1.6 mL), and the reaction mixture was heated to reflux for 1 h. The mixture was added 3% HCl (1 mL) and EtOAc (4 mL) and stirred until two clear phases appeared. The aqueous phase was added 3% HCl until pH < 1 and extracted with EtOAc. The combined organic phases were washed with brine, dried ($MgSO_4$) and concentrated to give 47 mg white foam: LC/MS (an10n8): Rt 2.93, m/z 243.0 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 5.69 (s, 2H), 7.13 (d, $J = 8.6$ Hz, 1H), 7.39-7.45 (m, 1H), 7.49-7.56 (m, 2H), 7.62-7.71 (m, 2H), 7.71-7.79 (m, 1H), 8.13 (s, 1H), 8.45 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 63.3, 115.6, 117.7, 120.3, 124.5, 128.6, 130.0, 131.2, 132.0, 132.9, 136.3, 139.1, 143.5, 154.7, 188.4.




3-(1-Phenyl-1H-pyrazole-4-carbonyl)biphenyl-4-yloxyacetic acid. Prepared from ethyl [4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetate and phenylboronic acid according to GP4: LC/MS (an10p8): Rt 1.05 min, m/z 398.6 [M – H][–]; ¹H NMR (CDCl₃): δ 4.86 (s, 2H), 7.17 (d, J = 8.6 Hz, 1H), 7.35-7.57 (m, 8H), 7.70-7.75 (m, 2H), 7.78 (dd, J = 8.6, 2.3 Hz, 1H), 7.84 (d, J = 2.3 Hz, 1H), 8.20 (s, 1H), 8.54 (s, 1H); ¹³C NMR (CDCl₃): δ 67.7, 115.8, 120.1, 124.8, 127.1, 128.0, 128.3, 129.1, 129.3, 129.4, 129.9, 132.3, 136.2, 139.3, 139.3, 143.5, 155.8, 170.4, 189.3.



Intermediate-5


(5-Bromo-2-hydroxyphenyl)-(1-pyridin-2-yl-1H-pyrazol-4-yl)ketone. To a suspension of 6-bromo-3-formylchromone (253 mg) in isopropanol (3 mL) and CH₂Cl₂ (2 mL) was added 2-hydrazinopyridine (109 mg), and the mixture was stirred for 15 min to form a yellow slurry. The slurry was added KOH (0.25 g) in water (0.25 mL), and the reaction was heated to reflux for 1 h. The reaction mixture was diluted with water, added 3% HCl until pH < 1 and extracted with CH₂Cl₂ (2x). The extract was washed with water and brine, dried (MgSO₄) and concentrated to give 342 mg orange foam, which was purified by flash chromatography (SiO₂, EA:Hep, 1:1) to give 53 mg (15%) yellow solid: LC/MS (an10p8): Rt 5.0 min, m/z 343.5 [M + H]⁺; ¹H NMR (CDCl₃): δ 6.98 (d, J = 8.9 Hz, 1H), 7.31 (ddd, J = 7.3, 4.9, 0.9 Hz, 1H), 7.60 (dd, J = 8.9, 2.5 Hz, 1H), 7.87-7.93 (m, 1H), 8.03 (d, J = 2.4 Hz, 1H), 8.04-8.09 (m, 1H), 8.02 (s, 1H), 8.47-8.51 (m, 1H), 9.13 (s, 1H), 11.94 (s, 1H); ¹³C NMR (CDCl₃): δ 110.9, 113.3, 120.8, 121.6, 122.8, 123.1, 130.5, 133.5, 138.9, 139.3, 143.3, 148.7, 161.9, 191.4.




Intermediate-6

Ethyl 4-bromo-2-(1-pyridin-2-yl-1H-pyrazole-4-carbonyl)phenoxyacetate.

Prepared from (5-bromo-2-hydroxyphenyl)-(1-pyridin-2-yl-1H-pyrazol-4-yl)ketone (43 mg) according to GP2 and purified by flash chromatography (SiO₂, EtOAc:heptane, 1:2) to give 34 mg (63%) of a pale yellow solid: LC/MS (an10p8): Rt 4.9 min, *m/z* 429.5 [M + H]⁺; ¹H NMR (CDCl₃): δ 1.23 (t, *J* = 7.2 Hz, 3H), 4.20 (q, *J* = 7.2 Hz, 2H), 4.62 (s, 2H), 6.76 (d, *J* = 8.6 Hz, 1H), 7.23-7.28 (m, 1H), 7.53 (ddd, *J* = 8.9, 2.6, 1.0 Hz, 1H), 7.58 (d, *J* = 2.5 Hz, 1H), 7.82-7.99 (m, 1H), 8.01 (d, *J* = 8.1 Hz, 1H), 8.19 (s, 1H), 8.40-8.44 (m, 1H), 8.99 (s, 1H); ¹³C NMR (CDCl₃): δ 14.3, 61.8, 66.1, 114.5, 114.7, 131.6, 132.3, 132.4, 134.6, 139.1, 148.5, 154.4, 168.3, 187.1.




4-Bromo-2-(1-pyridin-2-yl-1H-pyrazole-4-carbonyl)phenoxyacetic acid. Prepared from ethyl [4-bromo-2-(1-pyridin-2-yl-1H-pyrazole-4-carbonyl)phenoxy]-acetate (21 mg) according to GP3 to give 20 mg white foam: LC/MS (an10n8): Rt 2.8 min, *m/z* 401.9 [M - H]⁻; ¹H NMR (CDCl₃): δ 4.79 (s, 2H), 6.98 (d, *J* = 8.9 Hz, 1H), 7.28-7.34 (m, 1H), 7.67 (dd, *J* = 8.9, 2.5 Hz, 1H), 7.75 (d, *J* = 2.5 Hz, 1H), 7.86-7.94 (m, 1H), 8.02-8.08 (m, 1H), 8.22 (s, 1H), 8.43-8.48 (m, 1H), 9.04 (s, 1H).



(5-Bromo-2-hydroxy-phenyl)-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]ketone. To a suspension of 6-bromo-3-formylchromone (253 mg, 1.0 mmol) in ethanol (5 mL) was added 4-methoxyphenylhydrazine (175 mg, 1.0 mmol), and the mixture was stirred under argon for 12 h an orange slurry. The slurry was added KOH (260 mg) in water (0.25 mL), and the reaction was heated to reflux for 1½ h. The reaction mixture was added 3% HCl until pH <1 and left on ice to precipitate. The precipitate was filtered off and washed with a small amount of cold ethanol to give 256 mg (69%) beige solid that was used without further purification: LC/MS (an10p8): Rt 5.0 min, *m/z* 372.5 [M + H]⁺; ¹H NMR (CDCl₃): δ 3.88 (s, 3H), 6.98 (d, *J* = 8.9 Hz, 1H), 7.03 (d, *J* = 9.1 Hz, 2H), 7.59 (dd, *J* = 9.0, 2.5 Hz, 1H), 7.66 (d, *J* = 9.1 Hz, 2H), 8.02 (d, *J* = 2.4 Hz, 1H),


8.15 s, 1H), 8.39 (s, 1H), 11.92 (s, 1H); ^{13}C NMR (CDCl_3): δ 55.9, 110.9, 115.0, 120.8, 121.6, 121.8, 122.9, 130.7, 133.5, 138.8, 142.3, 159.7, 161.8.



Intermediate-8

Ethyl 4-bromo-2-[1-(4-methoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxyacetate.


Prepared from (5-bromo-2-hydroxyphenyl)-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]ketone and ethyl bromoacetate according to GP2: LC/MS (an10p8): Rt 4.59 min, m/z 458.4/460.4 $[\text{M} + \text{H}]^+$; ^1H NMR (CDCl_3): δ 1.26 (t, $J = 7.1$ Hz, 3H), 3.84 (s, 3H), 4.23 (q, $J = 7.1$ Hz, 2H), 4.62 (s, 2H), 6.72 (d, $J = 8.9$ Hz, 1H), 6.97 (d, $J = 8.7$ Hz, 2H), 7.52 (dd, $J = 8.9, 2.6$ Hz, 1H), 7.58 (d, $J = 2.5$ Hz, 1H), 7.64 (d, $J = 8.9$ Hz, 2H), 8.13 (s, 1H), 8.46 (s, 1H); ^{13}C NMR (CDCl_3): δ 14.3, 55.8, 61.9, 65.6, 114.1, 114.4, 114.8, 121.4, 125.0, 131.6, 132.4, 132.6, 133.2, 134.5, 142.5, 154.1, 159.2, 168.5, 186.9.




D7

4-Bromo-2-[1-(4-methoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.


Prepared from ethyl 4-bromo-2-[1-(4-methoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxyacetate (23 mg) according to GP3 to give 21 mg (97%) white foam: LC/MS (an10n8): Rt 5.76 min, m/z 428.9 $[\text{M} - \text{H}]^-$; ^1H NMR (CDCl_3): δ 3.86 (s, 3H), 4.77 (s, 2H), 6.94 (d, $J = 8.9$ Hz, 1H), 6.99 (d, $J = 9.2$ Hz, 2H), 7.59-7.66 (m, 3H), 7.71 (d, $J = 2.4$ Hz, 1H), 8.14 (d, $J = 0.6$ Hz, 1H), 8.40 (d, $J = 0.6$ Hz, 1H); ^{13}C NMR (CDCl_3): δ 55.9, 67.2, 115.0, 115.1, 116.6, 121.8, 124.2, 130.7, 131.8, 132.7, 133.2, 136.1, 143.2, 155.2, 159.7, 169.9, 187.6.

**D8****[3',5'-Difluoro-3-(1-phenyl-1H-pyrazole-4-carbonyl)biphenyl-4-yloxy]acetic acid.**


Prepared ethyl [4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetate and 3,5-difluorophenylboronic acid according to GP4: LC/MS (an10n8): Rt 3.03 min, m/z 434.5 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.85 (s, 2H), 6.81 (td, $J = 8.9, 2.3$ Hz, 1H), 7.07 (d, $J = 8.3$ Hz, 2H), 7.14 (d, $J = 8.9$ Hz, 1H), 7.41 (d, $J = 6.6$ Hz, 1H), 7.48 (s, 1H), 7.52 (d, $J = 8.5$ Hz, 1H), 7.66-7.78 (m, 4H), 8.23 (s, 1H), 8.57 (s, 1H)

**D9****[4'-Chloro-3-(1-phenyl-1H-pyrazole-4-carbonyl)biphenyl-4-yloxy]acetic acid.**

Prepared from ethyl [4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetate and 4-chlorophenylboronic acid according to GP4: LC/MS (an10n8): Rt 3.08 min, m/z 432.5 $[M - H]^-$.


**D10**

[4-Chloro-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid. Prepared from (2-hydroxy-5-chlorophenyl)-(1-phenyl-1H-pyrazol-4-yl)-methanone and ethyl bromoacetate according to GP2 and GP3: LC/MS (an10p8): Rt 3.08 min, m/z 356.6 $[M + 1]^+$; 1H NMR ($CDCl_3$): δ 4.75 (s, 2H), 6.95 (d, $J = 8.9$ Hz, 1H), 7.33-7.41 (m, 1H), 7.44-7.52 (m, 3H), 7.55 (d, $J = 2.6$ Hz, 1H), 7.69-7.75 (m, 2H), 8.18 (s, 1H), 8.52 (s, 1H).




D11

[4-Methyl-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid. Prepared from (2-hydroxy-5-methylphenyl)-(1-phenyl-1H-pyrazol-4-yl)-methanone and ethyl bromoacetate according to GP2 and GP3: LC/MS (an10p8): Rt 3.08 min, m/z 356.6 $[M + 1]^+$; $^1\text{H NMR}$ (CDCl_3): δ 2.37 (s, 3H), 4.78 (s, 2H), 6.97 (d, $J = 9.0$ Hz, 1H), 7.33-7.51 (m, 5H), 7.73 (d, $J = 6$ Hz, 2H), 8.16 (s, 1H), 8.51 (s, 1H), 11.21 (br s, 1H)




D12

[4-Chloro-3-methyl-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid. Prepared from (3-chloro-6-hydroxy-2-methyl-phenyl)-(1-phenyl-1H-pyrazol-4-yl)methanone and ethyl bromoacetate according to GP2 and GP3: LC/MS (an10p8): Rt 3.34 min, m/z 370.6 $[M + 1]^+$; $^1\text{H NMR}$ (CDCl_3): δ 2.44 (s, 3H), 4.77 (s, 2H), 6.92 (s, 1H), 7.39 (d, $J = 9.0$ Hz, 1H), 7.46-7.51 (m, 2H), 7.59 (s, 1H), 7.72 (d, $J = 9.0$ Hz, 2H), 8.19 (s, 1H), 8.52 (s, 1H), 10.39 (br s, 1H)



D13


[2,4-Dichloro-6-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid. Prepared from (3,5-dichloro-2-hydroxyphenyl)-(1-phenyl-1H-pyrazol-4-yl)methanone and ethyl bromoacetate according to GP2 and GP3: LC/MS (an10p8): Rt 3.27 min, m/z 390.5 $[M + 1]^+$; $^1\text{H NMR}$ (CDCl_3): δ 4.72 (s, 2H), 7.38-7.51 (m, 4H), 7.57-7.58 (m, 1H), 7.70 (d, $J = 8.1$ Hz, 2H), 8.06 (s, 1H), 8.36 (s, 1H), 9.23 (br s, 1H).




D14

4-Bromo-2-[1-(2-chloro-phenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.


Prepared from 6-bromo-3-formylchromone, 2-chlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8) Rt 3.02 min, m/z 436.4 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.76 (s, 2H), 6.94 (d, $J = 8.9$ Hz, 1H), 7.39-7.47 (m, 2H), 7.53-7.67 (m, 3H), 7.74 (dd, $J = 2.4, 0.9$ Hz, 1H), 8.21 (s, 1H), 8.40 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 67.2, 115.0, 116.7, 123.9, 127.9, 128.2, 128.7, 130.55, 130.59, 131.1, 133.3, 136.2, 136.6, 137.1, 143.1, 155.2, 170.0, 187.5.

**4-Bromo-2-[1-(3-chloro-phenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**


Prepared from 6-bromo-3-formylchromone and 3-chlorophenylhydrazine according to: LC/MS (an10p8) Rt 3.57 min, m/z 436.4 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.76 (s, 2H), 6.90 (d, $J = 8.9$ Hz, 1H), 7.34 (dm, $J = 6.8$ Hz, 1H), 7.41 (t, $J = 8.3$ Hz, 1H), 7.58-7.66 (m, 2H), 7.68 (d, $J = 2.0$ Hz, 1H), 7.78 (m, 1H), 8.17 (s, 1H), 8.51 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 66.8, 115.1, 116.2, 117.9, 120.4, 124.9, 128.3, 130.7, 131.0, 132.0, 133.2, 135.8, 136.1, 140.2, 143.4, 155.0, 170.1, 187.4.

**4-Bromo-2-[1-(4-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**


Prepared from 6-bromo-3-formylchromone, 4-bromophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8) Rt 3.75 min, m/z 480.3 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.75 (s, 2H), 6.89 (d, $J = 8.9$ Hz, 1H), 7.59-7.65 (m, 5H), 7.66-7.69 (m, 1H), 8.16 (s, 1H), 8.50 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 66.5, 115.0, 115.9, 121.5, 121.8, 124.9, 130.8, 131.8, 133.0, 133.1, 135.9, 138.2, 143.4, 154.8, 170.6, 187.4.

**D17****4-Bromo-2-[1-(4-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**


Prepared from 6-bromo-3-formylchromone, 4-chlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 3.53 min, m/z 436.4 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.74 (s, 2H), 6.88 (d, $J = 8.9$ Hz, 1H), 7.44 (d, $J = 8.5$ Hz, 2H), 7.61 (dd, $J = 8.9, 2.4$ Hz, 1H), 7.63-7.70 (m, 3H), 8.17 (s, 1H), 8.49 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 66.4, 114.9, 115.7, 121.2, 124.9, 130.0, 130.9, 131.9, 133.1, 133.9, 135.9, 137.7, 143.3, 154.7, 170.8, 187.4.

**D18****4-Bromo-2-[1-(2-ethylphenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**

Prepared from 6-bromo-3-formylchromone, 2-ethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.58 min, 427.0 m/z $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.14 (t, $J = 7.5$ Hz, 3H), 2.58 (q, $J = 7.5$, 2H), 4.76 (s, 2H), 6.93 (d, $J = 8.9$ Hz, 1H), 7.28-7.34 (m, 2H), 7.37-7.48 (m, 2H), 7.62 (dd, $J = 8.9, 2.6$ Hz, 1H), 7.72 (d, $J = 2.5$ Hz, 1H), 8.15 (s, 1H), 8.18 (s, 1H).


**D19****4-Nitro-2-[1-(4-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**

Prepared from 6-nitro-3-formylchromone, 4-chlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.44 min, m/z 401.7 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.84 (d, 2H), 7.1 (d, $J = 9.6$ Hz, 1H), 7.44 (d, $J = 8.1$ Hz, 2H), 7.67 (d, $J = 8.1$ Hz, 2H), 8.22 (s, 1H), 8.36 (d, $J = 9.2$ Hz, 1H), 8.41 (s, 1H), 8.53 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 65.6, 112.9, 121.3, 124.9, 126.2, 128.2, 130.0, 130.1, 131.9, 134.1, 137.6, 142.4, 143.3, 159.7, 169.9, 186.2.




D20

4-Nitro-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetic acid. Prepared from 6-nitro-3-formylchromone, 2-ethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8) Rt 2.05 min, m/z 367.8 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.83 (s, 2H), 7.01 (d, $J = 9.0$ Hz, 1H), 7.34-7.42 (m, 1H), 7.44-7.53 (m, 1H), 7.65-7.72 (m, 1H), 8.26 (s, 1H), 8.34 (dd, $J = 9.0, 2.6$ Hz, 1H), 8.41 (d, $J = 2.6$ Hz, 1H), 8.53 (s, 1H).




D21

4-Bromo-2-[1-(2-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid. Prepared from 6-bromo-3-formylchromone, 2-bromophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 3.38 min, m/z 480.6 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.75 (s, 2H), 6.91 (d, $J = 9.0$ Hz, 1H), 7.34-7.64 (m, 6H), 7.73-7.74 (m, 2H), 8.22 (s, 1H), 8.36 (s, 1H).




D22


4-Bromo-2-[1-(2-fluorophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid. Prepared from 6-bromo-3-formylchromone, 2-fluorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 3.36 min, m/z 418.7 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.75 (s, 2H), 6.91 (d, $J = 8.9$ Hz, 1H), 7.21-7.42 (m, 3H), 7.62 (dd, $J = 8.9, 2.4$ Hz, 1H), 7.70 (d, $J = 2.5$ Hz, 1H), 7.85-7.92 (m, 1H), 8.20 (s, 1H), 8.51 (d, $J = 2.3$ Hz, 1H); ^{13}C NMR ($CDCl_3$): δ 66.9, 115.0, 116.3, 117.1, 117.4, 124.62, 124.63, 125.0, 125.39, 125.44, 127.4, 127.5, 129.6, 129.7, 130.8, 133.2, 135.8, 136.8, 143.0, 152.3, 155.0, 155.6, 170.5, 187.4.

**D23**


4-Bromo-2-[1-(2-trifluoromethylphenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid. Prepared from 6-bromo-3-formylchromone, 2-trifluoromethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 3.44 min, m/z 468.7 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.72 (s, 2H), 6.89 (d, $J = 8.9$ Hz, 1H), 7.53-7.75 (m, 5H), 7.84 (d, $J = 7.9$ Hz, 1H), 8.20 (s, 2H); ^{13}C NMR ($CDCl_3$): δ 66.8, 114.9, 116.2, 124.3, 126.3, 126.7, 127.58, 127.64, 129.2, 130.3, 130.7, 133.2, 136.0, 136.9, 143.1, 155.0, 170.3, 187.4.

**D24**


4-Bromo-2-[1-(3-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid. Prepared from 6-bromo-3-formylchromone, 3-bromophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 4.29 min, m/z 480.5 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.79 (s, 2H), 6.95 (d, $J = 9.0$ Hz, 1H), 7.28-7.40 (m, 1H), 7.53 (d, $J = 9$ Hz, 1H), 7.65 -7.73 (m, 3H), 7.96 (s, 1H), 8.18 (s, 1H); 8.51 (s, 1H).

**D25**


4-Bromo-2-[1-(3-trifluoromethylphenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid. Prepared from 6-bromo-3-formylchromone, 3-trifluoromethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 4.54 min, m/z 468.7 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.76 (s, 2H), 6.89 (d, $J = 8.9$ Hz, 1H), 7.57-7.66 (m, 3H), 7.68 (d, $J = 2.4$ Hz, 1H), 7.89-7.96 (m, 1H), 8.04 (s, 1H), 8.20 (s, 1H), 8.59 (s, 1H), 9.15 (br s, 1H).

**D26****4-Bromo-2-[1-(2,4-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**


Prepared from 6-bromo-3-formylchromone, 2,4-dichlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 4.35 min, m/z 468.6 $[M + H]^+$; 1H NMR (DMSO- d_6): δ 4.76 (s, 2H), 7.03 (d, $J = 9.0$ Hz, 1H), 7.52 (m, 1H), 7.57-7.69 (m, 3H), 7.89 (m, 1H), 8.19 (s, 1H), 8.69 (s, 1H); ^{13}C NMR (DMSO- d_6): δ 55.8, 103.6, 106.2, 115.2, 119.5, 120.6, 120.7, 121.1, 122.4, 125.5, 125.6, 127.1, 128.3, 133.4, 145.1, 160.9, 177.4.

**D27****4-Nitro-2-[1-(2-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**

Prepared from 6-nitro-3-formylchromone 2-chlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.42 min, m/z 401.8 $[M + H]^+$; 1H NMR (CDCl $_3$): δ 4.83 (s, 2H), 7.01 (d, $J = 9.0$ Hz, 2H), 7.42-7.48 (m, 2H), 7.56-7.63 (m, 2H), 8.34-8.40 (m, 2H), 8.5 (s, 2H).

**D28****4-Nitro-2-[1-(2-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**


Prepared from 6-nitro-3-formylchromone, 2-bromophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.33 min, m/z 445.9 $[M - H]^+$; 1H NMR (CDCl $_3$): δ 4.85 (s, 2H), 7.04 (d, $J = 9$ Hz, 1H), 7.37-7.81 (m, 4H), 8.32-8.44 (m, 3H), 8.50 (s, 1H).



D29

4-Bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.


Prepared from 6-bromo-3-formylchromone, 2,6-dichlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.56 min, m/z 468.6 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.72, 6.88 (d, $J = 8.9$ Hz, 1H), 7.37-7.44 (m, 1H), 7.45-7.52 (m, 2H), 7.59 (d, $J = 8.7$ Hz, 1H), 7.70 (m, 1H), 8.14 (s, 1H), 8.26 (s, 1H).



D30

4-Ethyl-2-[1-(2-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.


Prepared from 6-ethyl-3-formylchromone, 2-bromophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.88 min, m/z 428.8 $[M + H]^+$.



D31

2-[1-(2-Chlorophenyl)-1H-pyrazole-4-carbonyl]-4-isopropylphenoxyacetic acid.


Prepared from 6-isopropyl-3-formylchromone, 2-chlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.83 min, m/z 398.8 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 1.28 (d, $J = 7.0$ Hz, 6H), 2.93 (septet, $J = 6.9$ Hz, 1H), 4.82 (s, 2H), 7.04 (d, $J = 8.5$ Hz, 1H), 7.40-7.65 (m, 6H), 8.28 (s, 1H), 8.40 (s, 1H).




D32

{4-Bromo-2-[1-(4-trifluoromethoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.


Prepared from 6-bromo-3-formylchromone, 4-trifluoromethoxyphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 3.24 min, m/z 484.6 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.75 (s, 2H), 6.89 (d, $J = 8.9$ Hz, 1H), 7.34 (d, $J = 9.0$ Hz, 2H), 7.61 (dd, $J = 8.9, 2.6$ Hz, 1H), 7.67 (m, 1H), 7.72-7.80 (m, 2H), 8.17 (s, 1H), 8.51 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 66.5, 115.0, 115.8, 121.4, 122.5, 125.0, 130.8, 132.0, 133.1, 136.0, 137.6, 143.4, 148.6, 148.7, 154.8, 170.8, 187.4.

**4-Bromo-2-[1-(2,4-dibromophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**


Prepared from 6-bromo-3-formylchromone, 2,4-dibromophenylhydrazine according and ethyl bromoacetate to GP1, GP2 and GP3: LC/MS (an10p8): Rt 3.41 min, m/z 556.4 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.75 (s, 2H), 6.92 (d, $J = 9.0$ Hz, 1H), 7.45 (d, $J = 8.5$ Hz, 1H), 7.63 (m, 2H), 7.73 (d, $J = 2.5$ Hz, 1H), 7.92 (d, $J = 2.1$ Hz, 1H), 8.22 (s, 1H), 8.37 (s, 1H).

**4-Bromo-2-[1-(4-bromo-2-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid.**


Prepared from 6-bromo-3-formylchromone, 4-bromo-2-chlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 3.34 min, m/z 512.5 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.78 (s, 2H), 6.95 (d, $J = 8.6$ Hz, 1H), 7.51-7.76 (m, 5H), 8.21 (s, 1H), 8.42 (s, 1H).



4-Bromo-2-[1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxyacetic acid. Prepared from 6-bromo-3-formylchromone, 2,4,6-trichlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 3.35 min, m/z 502.6 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.91 (s, 2H), 7.05 (d, $J = 8.9$ Hz, 1H), 7.68 (s, 2H), 7.78 (d, $J = 8.5$ Hz, 1H), 7.88 (s, 1H), 8.31 (s, 1H), 8.43 (s, 1H), 9.03 (br s, 1H).



4-Methoxy-2-[1-phenyl-1H-pyrazole-4-carbonyl]phenoxyacetic acid. Prepared from 6-bromo-3-formylchromone, 2,4-dichlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.46 min, m/z 350.9 $[M - H]^+$; 1H NMR ($CDCl_3$): δ 3.81 (s, 3H), 4.77 (s, 2H), 7.02-7.16 (m, 3H), 7.41 (d, $J = 7.5$ Hz, 1H), 7.50 (t, $J = 8.1$ Hz, 2H), 7.73 (d, $J = 8.5$ Hz, 2H), 8.17 (s, 1H), 8.52 (s, 1H).




2-[4-Bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]propionic acid.


Prepared from (5-bromo-2-hydroxyphenyl)-(1-phenyl-1H-pyrazol-4-yl)ketone and ethyl 2-bromopropionate according to GP2 and GP3: LC/MS (an10p8) Rt 2.51 min, m/z 415 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 1.65 (d, $J = 6.8$ Hz, 3H), 4.93 (q, $J = 6.8$ Hz, 1H), 6.96 (d, $J = 8.9$ Hz, 1H), 7.35-7.43 (m, 1H), 7.46-7.53 (m, 2H), 7.62 (dd, $J = 8.9$, 2.5 Hz, 1H), 7.70-7.76 (m, 3H), 8.17 (s, 1H), 8.52 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 18.8, 75.2, 114.8, 116.7, 120.1, 124.4, 128.3, 130.0, 133.3, 136.2, 139.2, 143.3, 155.0, 173.1, 187.8.

2(S)-[4-Bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)-phenoxy]-propionic acid. (5-Bromo-2-hydroxyphenyl)-(1-phenyl-1H-pyrazol-4-yl)ketone (100 mg, 0.29 mmol), (R)-(+)-bromoacetic acid (44 mg, 0.29 mmol) ethyl 2-bromopropionate and K_2CO_3 (80 mg, 0.58 mmol) in acetone was stirred at room temperature for 16 h. The reaction mixture was concentrated and the residue was partitioned between EtOAc and dilute HCl (pH ~1). The organic phase was dried (Na_2SO_4) and concentrated, and the


residue was purified by flash chromatography (EtOAc:heptane, 1:1) to yield 55 mg (46%) of the title compound: Chiral HPLC (Column: Ciracel OD (0.46 cm x 24 cm); Eluent: isocratic, 85% hexane + 15% 2-propanol + 0.1% TFA; Flow 0.5 mL/min) Rt 15.7 min, >90% e.e. (Racemic material eluates with baseline separation of enantiomers: Rt 15.7 and 16.7 min.) MS and NMR spectra correspond to racemic material.



2-{4-Bromo-2-[1-(2-chlorophenyl)-1-H-pyrazole-4-carbonyl]phenoxy}propionic acid. Prepared from 6-bromo-3-formylchromone, 2-chlorophenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.56 min, 448.9 m/z $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.65 (d, $J = 7.0$ Hz, 3H), 4.93 (q, $J = 7.0$ Hz, 1H), 6.96 (d, $J = 8.9$ Hz, 1H), 7.41-7.47 (m, 2H), 7.55-7.64 (m, 3H), 7.74 (s, 1H), 8.23 (s, 1H), 8.42 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 18.9, 75.4, 115.0, 117.0, 124.1, 128.1, 128.4, 128.9, 130.7, 131.3, 133.6, 136.4, 136.8, 137.3, 143.3, 155.2, 173.5, 188.0.




2-{4-Bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid. Prepared from 6-bromo-3-formylchromone, 2,6-dichlorophenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.55 min, 482.9 m/z $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.65 (d, $J = 6.8$ Hz, 3H), 4.91 (q, $J = 6.8$ Hz, 1H), 6.93 (d, $J = 8.9$ Hz, 1H), 7.41-7.53 (m, 3H), 7.62 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.74 (d, $J = 2.4$, 1H), 8.17 (s, 1H), 8.28 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 18.9, 75.1, 114.9, 116.8, 124.2, 129.3, 130.7, 132.0, 133.6, 134.5, 135.6, 136.4, 137.6, 143.6, 155.1, 173.6, 187.8.




D40 {4-Bromo-2-[1-(2-cyano-phenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.

Prepared from 6-bromo-3-formylchromone, 2-hydrazinobenzonitril (prepared according to van der Mey, et al. *J. Med. Chem.* **2003**, 2008-2016) and ethyl bromoacetate according to GP1, GP2 and GP3: ^1H NMR ($\text{DMSO}-d_6$): δ 4.72 (s, 2H), 7.17 (d, $J = 8.9$ Hz, 1H), 7.36 (t, $J = 15.1, 7.3$ Hz, 1 H), 7.8 (m, 4H), 8.29 (d, $J = 8.3$ Hz, 1 H), 9.03 (s, 1 H), 9.66 (s, 1H), 13.04 (br s, 1H).




D41 {4-Bromo-2-[1-(2-ethoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.

Prepared from 6-bromo-3-formylchromone, 2-ethoxyphenylhydrazine and ethyl 2-bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.33 min, m/z 446.7 $[\text{M} + \text{H}]^+$; ^1H NMR (CDCl_3): δ 1.47 (t, $J = 7.0$ Hz, 3H), 4.18 (q, $J = 7.0$ Hz, 2H), 4.78 (s, 2H), 6.97 (d, $J = 8.9$ Hz, 1H), 7.09 (d, $J = 8.7$ Hz, 2H), 7.36 (td, $J = 7.9, 1.8$ Hz, 1H), 7.64 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.79 (d, $J = 2.5$ Hz, 1H), 7.80 (dd, $J = 7.9, 1.6$ Hz, 1H), 8.22 (s, 1H), 8.65 (s, 1H).




D42 {4-Bromo-2-[1-(4-bromo-2-ethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.


Prepared from 6-bromo-3-formylchromone, 4-bromo-2-ethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.78 min, m/z 506.6 $[\text{M} - \text{H}]^-$; ^1H NMR (CDCl_3): δ 1.16 (td, $J = 7.8, 2.4$ Hz, 3H), 2.58 (qd, $J = 7.8, 1.8$ Hz, 2H), 4.77 (s, 2H), 6.94 (d, $J = 9.0$ Hz, 1H), 7.22 (d, $J = 8.5$ Hz, 1H), 7.47 (d, $J = 8.5$ Hz, 1H), 7.56 (s, 1H), 7.65 (d, $J = 8.7$ Hz, 1H), 7.72 (s, 1H), 8.15 (s, 1H), 8.19 (s, 1H).

**D43****{4-Bromo-2-[1-(2-phenoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.**

Prepared from 6-bromo-3-formylchromone, 4-bromo-2-ethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.77 min, m/z 492.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 4.75 (s, 2H), 6.95 (d, $J = 8.6$ Hz, 1H), 7.00-7.09 (m, 3H), 7.15 (t, $J = 7.5$ Hz, 1H), 7.29-7.40 (m, 4H), 7.62-7.68 (m, 2H), 7.90 (d, $J = 9.0$ Hz, 1H), 8.17 (s, 1H), 8.60 (s, 1H).


**D44****{4-Bromo-2-[1-(2-methylthiophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.**

Prepared from 6-bromo-3-formylchromone, 2-methylthiophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.26 min, m/z 446.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 2.46 (s, 3H), 4.77 (s, 2H), 6.93 (d, $J = 8.9$ Hz, 1H), 7.28-7.32 (m, 1H), 7.39-7.49 (m, 3H); 7.62 (dd, $J = 9.0, 2.5$ Hz, 1H), 7.76 (s, 1H), 8.23 (s, 1H), 8.31 (s, 1H).

**D45****{4-Bromo-2-[1-(2-bromo-4-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}-**

acetic acid. Prepared from 6-bromo-3-formylchromone, 2-bromo-4-methylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS

(an10n8): Rt 2.47 min, m/z 492.6 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 2.44 (s, 3H), 4.80 (s, 2H), 6.99 (d, $J = 8.9$ Hz, 1H), 7.27-7.30 (m, 1H), 7.46 (d, $J = 8.1$ Hz, 1H), 7.58 (s, 1H), 7.67 (d, $J = 9.0$ Hz, 1H), 7.80 (s, 1H), 8.20 (s, 1H), 8.33 (s, 1H).




D46

2-{4-Bromo-2-[1-(4-bromo-2-ethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}-propionic acid. Prepared from 6-bromo-3-formylchromone, 4-bromo-2-

ethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3:


LC/MS (an10p8): Rt 2.72 min, m/z 522.6 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 1.16 (t, $J = 7.7$ Hz, 3H), 1.67 (d, $J = 6.8$ Hz, 3H), 2.59 (q, $J = 7.5$ Hz, 2H), 4.95 (q, $J = 7.0$ Hz, 1H), 6.96 (d, $J = 9.0$ Hz, 1H), 7.21 (d, $J = 8.3$ Hz, 1H), 7.47 (d, $J = 8.7$ Hz, 1H), 7.55 (s, 1H), 7.63 (d, $J = 9.0$ Hz, 1H), 7.73 (s, 1H), 8.17 (s, 1H), 8.18 (s, 1H).



D47

2-{4-Bromo-2-[1-(2-phenoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid. Prepared from 6-bromo-3-formylchromone, 2-phenoxyphenylhydrazine and

ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.68 min, m/z 508.7 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 1.65 (d, $J = 6.8$ Hz, 3H), 4.92 (q, $J = 7.3$ Hz, 1H), 6.96-7.18 (m, 5H), 7.26-7.39 (m, 4H), 7.62 (d, $J = 8.6$ Hz, 1H), 7.67 (s, 1H), 7.90 (d, $J = 7.5$ Hz, 1H), 8.17 (s, 1H), 8.61 (s, 1H).




D48

2-{4-Bromo-2-[1-(2-ethoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid. Prepared from 6-bromo-3-formylchromone, 2-ethoxyphenylhydrazine and ethyl

2-bromopropionate according to GP1, GP2 and GP3:


LC/MS (an10p8): Rt 2.39 min, m/z 458.7 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 1.49 (t, $J = 7.1$ Hz, 3H), 1.86 (d, $J = 7.1$ Hz, 3H), 4.19 (m, 2H), 4.98 (q, $J = 6.9$ Hz, 1H), 7.02-7.12 (m, 3H), 7.37 (t, $J = 8.2$ Hz, 1H), 7.66 (d, $J = 8.9$ Hz, 1H), 7.78 (s, 1H), 7.83 (d, $J = 7.9$ Hz, 1H), 8.20 (s, 1H), 8.67 (s, 1H).



D49

2-{4-Bromo-2-[1-(2-methylthio)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid.


Prepared from 6-bromo-3-formylchromone, 2-ethoxyphenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.56 min, 460.9 m/z $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.71 (d, $J = 6.8$ Hz, 3H), 2.46 (s, 3H), 4.96 (q, $J = 7.0$ Hz, 1H), 7.00 (d, $J = 8.9$ Hz, 1H), 7.29-7.34 (m, 1H), 7.40-7.50 (m, 3H), 7.64 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.80 (s, 1H), 8.22 (s, 1H), 8.32 (s, 1H).



D50

2-{4-Bromo-2-[1-(2-bromo-4-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid.


Prepared from 6-bromo-3-formylchromone, 2-bromo-4-methylphenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.74 min, 506.8 m/z $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.72 (d, $J = 7.0$ Hz, 3H), 2.45 (s, 3H), 4.98 (q, $J = 7.0$ Hz, 1H), 7.03 (d, $J = 8.9$ Hz, 1H), 7.28-7.30 (m, 1H), 7.46 (d, $J = 8.1$ Hz, 1H), 7.59 (s, 1H), 7.67 (dd, $J = 8.9, 2.43$ Hz, 1H), 7.81 (d, $J = 2.6$ Hz, 1H), 8.19 (s, 1H), 8.34 (s, 1H).




D51

2-{4-Bromo-2-[1-(2,4-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid.


Prepared from 6-bromo-3-formylchromone, 2,4-dichlorophenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.83 min, 482.8 m/z $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.50 (d, $J = 6.0$ Hz, 3H), 4.75 (q, $J = 4.5$ Hz, 1H), 6.88 (d, $J = 8.5$ Hz, 1H), 7.40 (dd, $J = 8.5, 1.9$ Hz, 1H), 7.50 (d, $J = 7.5$ Hz, 1H), 7.54-7.57 (m, 2H), 7.61 (s, 1H), 8.16 (s, 1H), 8.32 (s, 1H).

**D52****{4-Bromo-2-[1-(2-trifluoromethoxyphenyl)-1H-pyrazole-4-**


carbonyl]phenoxy}acetic acid. Prepared from 6-bromo-3-formylchromone, 2-trifluoromethoxyphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.43 min, m/z 482.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 4.77 (s, 2H), 6.95 (d, $J = 8.6$ Hz, 1H), 7.45-7.50 (m, 3H), 7.65 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.73 (d, $J = 2.4$ Hz, 1H), 7.82 (s, 1H), 8.23 (s, 1H), 8.40 (s, 1H).

**D53****{2-[1-(2,6-Dichlorophenyl)-1H-pyrazole-4-carbonyl]-4-ethylphenoxy}acetic acid.**

Prepared from 6-ethyl-3-formylchromone, 2,6-dichlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.25 min, m/z 416.8 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 1.26 (t, $J = 7.5$ Hz, 3H), 2.69 (q, $J = 7.7$ Hz, 2H), 4.82 (s, 2H), 7.04 (d, $J = 8.7$ Hz, 1H), 7.39-7.44 (m, 1H), 7.46-7.54 (m, 4H), 8.14 (s, 1H), 8.25 (s, 1H).


**D54****{4-Bromo-2-[1-(2,4-dimethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic**

acid. Prepared from 6-bromo-3-formylchromone, 2,4-dimethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.41 min, m/z 428.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 2.26 (s, 3H), 2.40 (s, 3H), 4.75 (s, 2H), 6.91 (d, $J = 8.9$ Hz, 1H), 7.11 (d, $J = 8.1$ Hz, 1H), 7.17 (s, 1H), 7.23 (d, $J = 8.1$ Hz, 1H), 7.60 (dd, $J = 8.9, 2.46$ Hz, 1H), 7.71 (s, 1H), 8.15 (s, 1H), 8.22 (s, 1H).




D55

2-{4-Bromo-2-[1-(2,4-dimethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}-propionic acid. Prepared from 6-bromo-3-formylchromon, 2,4-dimethylphenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.40 min, m/z 442.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 1.67 (d, $J = 6.9$ Hz, 3H), 2.25 (s, 3H), 2.40 (s, 3H), 4.93 (q, $J = 6.8$ Hz, 1H), 6.97 (d, $J = 8.9$ Hz, 1H), 7.12 (d, $J = 8.1$ Hz, 1H), 7.17 (s, 1H), 7.25 (d, $J = 8.1$ Hz, 1H), 7.62 (dd, $J = 8.7, 1.52$ Hz, 1H), 7.73 (s, 1H), 8.15-8.16 (m, 2H).




D56

[2-(1-Benzyl-1H-pyrazole-4-carbonyl)-4-bromophenoxy]acetic acid. Prepared from 6-bromo-3-formylchromone, benzylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.14 min, m/z 414.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 4.70 (s, 2H), 5.36 (s, 2H), 6.88 (d, $J = 8.7$ Hz, 1H), 7.28-7.30 (m, 2H), 7.40-7.46 (m, 3H), 7.57 (d, $J = 8.9$ Hz, 1H), 7.63 (s, 1H), 8.01 (s, 1H), 8.04 (s, 1H).




D57

2-[2-(1-Benzyl-1H-pyrazole-4-carbonyl)-4-bromophenoxy]propionic acid. Prepared from 6-bromo-3-formylchromone, benzylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.16 min, m/z 428.8 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 1.59 (d, $J = 6.8$ Hz, 3H), 4.88 (q, $J = 7.1$ Hz, 1H), 5.35 (s, 2H), 6.91 (d, $J = 8.9$ Hz, 1H), 7.30-7.42 (m, 5H), 7.53-7.71 (m, 2H), 8.01 (s, 2H).

**D58****{4-Bromo-2-[1-(4-chloro-2-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}-**


acetic acid. Prepared from 6-bromo-3-formylchromone, 4-chloro-2-methylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS

(an10n8): Rt 2.49 min, m/z 448.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 2.27 (s, 3H), 4.75 (s, 2H), 6.91 (d, $J = 8.9$ Hz, 1H), 7.31 (s, 2H), 7.36 (s, 1H), 7.63 (d, $J = 8.7$ Hz, 1H), 7.70 (s, 1H), 8.17 (s, 1H), 8.21 (s, 1H).


**D59****{4-Bromo-2-[1-(2,5-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic**

acid. Prepared from 6-bromo-3-formylchromone, 2,5-dichlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.46 min,


m/z 468.6 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 4.78 (s, 2H), 6.92 (d, $J = 8.9$ Hz, 1H), 7.39 (dd, $J = 8.7, 2.44$ Hz, 1H), 7.50 (d, $J = 8.7$ Hz, 1H), 7.61 (dd, $J = 8.9, 2.53$ Hz, 1H), 7.70 (dd, $J = 8.1, 2.36$ Hz, 2H), 8.22 (s, 1H), 8.45 (s, 1H).

**D60****{4-Bromo-2-[1-(2-methoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.**


Prepared from 6-bromo-3-formylchromone, 2-methylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.20 min, m/z 430.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 3.96 (s, 3H), 4.79 (s, 2H), 6.96 (d, $J = 8.9$ Hz, 1H), 7.11 (t, $J = 8.2$ Hz, 2H), 7.40 (t.d, $J = 8.1, 1.5$ Hz, 1H), 7.65 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.76 (d, $J = 2.5$ Hz, 2H), 8.18 (s, 1H), 8.60 (s, 1H).

**D61**


{4-Bromo-2-[1-(3,4-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid. Prepared from 6-bromo-3-formylchromone, 3,4-chlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.77 min, m/z 468.6 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 4.78 (s, 2H), 6.90 (d, $J = 8.7$ Hz, 1H), 7.59 (d, $J = 8.1$ Hz, 1H), 7.64 (d, $J = 8.9$ Hz, 1H), 7.69 (d, $J = 2.43$ Hz, 2H), 7.91 (d, $J = 2.46$ Hz, 1H), 8.18 (s, 1H), 8.53 (s, 1H).

**D62**


2-{4-Bromo-2-[1-(4-chloro-2-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}-propionic acid. Prepared from 6-bromo-3-formylchromone, 4-chloro-2-methylphenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.55 min, m/z 462.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 1.65 (d, $J = 6.9$ Hz, 3H), 2.28 (s, 3H), 4.92 (d, $J = 6.8$ Hz, 1H), 6.95 (d, $J = 8.9$ Hz, 1H), 7.30 (s, 2H), 7.37 (s, 1H), 7.63 (d, $J = 8.9$ Hz, 1H), 7.72 (s, 1H), 8.19 (s, 2H).

**D63**


2-{4-Bromo-2-[1-(2,5-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}-propionic acid. Prepared from 6-bromo-3-formylchromone, 2,5-dichlorophenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.51 min, m/z 482.6 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 1.70 (d, $J = 6.8$ Hz, 3H), 4.90 (q, $J = 6.9$ Hz, 1H), 6.93 (d, $J = 9.1$ Hz, 1H), 7.40 (dd, $J = 8.7, 2.5$ Hz, 1H), 7.50 (d, $J = 8.6$ Hz, 1H), 7.62 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.68 (d, $J = 2.3$ Hz, 1H), 7.71 (d, $J = 2.4$ Hz, 1H), 8.22 (s, 1H), 8.45 (s, 1H).

**D64**


2-{4-Bromo-2-[1-(3,4-dichloro-phenyl)-1H-pyrazole-4-carbonyl]phenoxy}-propionic acid. Prepared from 6-bromo-3-formylchromon, 3,4-dichlorophenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.83 min, m/z 482.6 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 1.63 (d, $J = 6.8$ Hz, 3H), 4.93 (q, $J = 6.9$ Hz, 1H), 6.92 (d, $J = 9.03$ Hz, 1H), 7.55-7.65 (m, 3H), 7.70 (s, 1H), 7.93 (d, $J = 2.25$ Hz, 1H), 8.20 (s, 1H), 8.57 (s, 1H).

**D65**

2-{4-Bromo-2-[1-(2-methoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid. Prepared from 6-ethyl-3-formylchromone, 2,6-dichlorophenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.23 min, m/z 444.7 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 1.68 (d, $J = 7.0$ Hz, 3H), 3.95 (s, 3H), 4.95 (d, $J = 7.0$ Hz, 1H), 6.99 (d, $J = 8.7$ Hz, 1H), 7.10 (d, $J = 8.5$ Hz, 1H), 7.14 (s, 1H), 7.37-7.43 (m, 1H), 7.63 (dd, $J = 8.9, 2.6$ Hz, 1H), 7.77 (s, 1H), 7.79 (s, 1H), 8.19 (s, 1H), 8.62 (s, 1H).


**D66**

[4-Amino-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid. A mixture of ethyl 4-nitro-2-(phenyl-1H-pyrazole-4-carbonyl)phenoxyacetate (190 mg, 0.48 mmol) and 10% Pd/C (100 mg) in MeOH (50 mL) was stirred under an atmosphere of hydrogen of 12 h, then filtered through a pad of celite and concentrated, and the product was hydrolyzed according to GP3 to give the title compound.


**D67****{4-Bromo-2-[1-(4-bromo-2-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}-**

acetic acid. Prepared from 6-bromo-3-formylchromone, 4-bromo-2-chlorophenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS


(an10n8): Rt 2.57 min, m/z 526.6 $[M - H]^-$; 1H NMR (DMSO): δ 1.31 (d, $J = 6.8$ Hz, 3H), 4.94 (q, $J = 6.6$ Hz, 1H), 6.92 (d, $J = 8.9$ Hz, 1H), 7.53 (d, $J = 2.5$ Hz, 1H), 7.59 (d, $J = 8.5$ Hz, 1H), 7.66 (dd, $J = 9.0, 2.5$ Hz, 1H), 7.76 (dd, $J = 8.5, 2.3$ Hz, 1H), 8.04 (d, $J = 2.1$ Hz, 1H), 8.22 (s, 1H), 8.77 (s, 1H).

**D68****2-[4-Bromo-2-[1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}-**


propionic acid. Prepared from 6-bromo-3-formylchromone, 2,4,6-trichlorophenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.61 min, m/z 516.6 $[M - H]^+$; 1H NMR (DMSO): δ 1.33 (d, $J = 6.8$ Hz, 3H), 4.94 (q, $J = 7.0$ Hz, 1H), 6.92 (d, $J = 9.2$ Hz, 1H), 7.54 (d, $J = 2.4$ Hz, 1H), 7.66 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.99 (s, 2H), 8.26 (s, 1H), 8.72 (s, 1H).

**D69****2-[4-Bromo-2-[1-(2,4-dibromophenyl)-1H-pyrazole-4-carbonyl]phenoxy}-**


propionic acid. Prepared from 6-bromo-3-formylchromone, 2,4-dibromophenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.87 min, m/z 572.7 $[M + H]^+$; 1H NMR (DMSO): δ 1.32 (d, $J = 6.8$ Hz, 3H), 4.93 (q, $J = 6.8$ Hz, 1H), 6.91 (d, $J = 8.9$ Hz, 1H), 7.54 (dd, $J = 8.3, 2.3$ Hz, 2H), 7.66 (dd, $J = 8.9, 2.5$ Hz, 1H), 7.78 (dd, $J = 8.6, 2.2$ Hz, 1H), 8.15 (d, $J = 2.1$ Hz, 1H), 8.21 (s, 1H), 8.72 (s, 1H).

**D70****{4-Bromo-2-[1-(2,6-diethyl-phenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.**


Prepared from 6-bromo-3-formylchromone, 2,6-diethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.54 min, m/z 457.0 $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.27 (t, $J = 7.3$ Hz, 6H), 2.35 (q, $J = 7.3$ Hz, 4H), 4.82 (s, 2H), 6.99 (d, $J = 8.9$ Hz, 1H), 7.29 (d, $J = 7.5$ Hz, 2H), 7.48 (m, 1H), 7.67 (m, 1H), 7.79 (s, 1H), 8.11 (s, 1H), 8.27 (s, 1H), 8.87 (br s, 1H).

**D71****{4-Bromo-2-[1-(2,6-dimethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.**


Prepared from 6-bromo-3-formylchromone, 2,6-diethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.27 min, m/z 428.9 $[M - H]^+$; 1H NMR ($CDCl_3$): δ 2.07 (s, 6H), 4.74 (s, 2H), 6.91 (d, $J = 8.7$ Hz, 1H), 7.19 (d, $J = 7.3$ Hz, 2H), 7.25-7.35 (m, 1H), 7.55-7.66 (m, 1H), 7.71 (s, 1H), 8.06 (s, 1H), 8.23 (s, 1H), 8.91 (br s, 1H).

**D72****{4-Bromo-2-[1-(2-ethyl-6-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid.**


Prepared from 6-bromo-3-formylchromone, 2-ethyl-6-methylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.43 min, m/z 443.0 $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.12 (t, $J = 7.8$ Hz, 3H), 2.05 (s, 3H), 2.33 (q, $J = 7.8$ Hz, 2H), 4.76 (s, 2H), 6.94 (d, $J = 8.7$ Hz, 1H), 7.14-7.25 (m, 2H), 7.31-7.41 (m, 1H), 7.56-66 (m, 1H), 7.72 (s, 1H), 8.06 (s, 1H), 8.22 (s, 1H), 8.93 (br s, 1H).

**D73**

{4-Bromo-2-[1-(2-isopropylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid. Prepared from 6-bromo-3-formylchromone, 2-ethyl-6-methylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.76 min, m/z 444.9 $[M + H]^+$; 1H NMR ($CDCl_3$ -d): δ 1.22 (d, $J = 6.5$ Hz, 6H), 2.89 (septet, $J = 6.1$ Hz, 1H), 4.76 (s, 2H), 6.92 (d, $J = 8.7$ Hz, 1H), 7.30 (s, 2H), 7.49 (s, 2H), 7.62 (d, 1H), 7.72 (s, 1H), 8.15 (s, 1H), 8.20 (s, 1H), 8.92 (br s, 1H).


**D74**

[4-Ethoxy-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid. Prepared from 6-ethoxy-3-formylchromone, phenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 1.97 min, m/z 367.1 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 1.43 (t, $J = 6.8$ Hz, 3H), 4.03 (q, $J = 6.9$ Hz, 2H), 4.78 (s, 2H), 7.01-7.13 (m, 2H), 7.15 (s, 1H), 7.36-7.43 (m, 1H), 7.46-7.57 (m, 2H), 7.71-7.75 (m, 2H), 8.16 (s, 1H), 8.50 (s, 1H).

**D75**


[4-Butyl-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid. A solution of ethyl [4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]acetate (472 mg, 1.1 mmol), 1-butylboronic acid (102 mg, 1.0 mmol) and Pd (dppf) Cl_2 (72 mg, 0.05 mmol) in THF (10 mL) and water (1 mL) under argon was refluxed for 24 h. The reaction mixture was extracted with CH_2Cl_2 , the organic phase was filtered through celite and concentrated, and the residue was purified by flash chromatography (SiO₂, EtOAc:heptane, 1:10 to 1:1). The purest fraction was concentrated (~10 mg), and the residue was hydrolysed according to GP3: LC/MS (an10p8): Rt 2.59 min, m/z 379.1 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 0.88 (t, $J = 7.5$ Hz, 3H), 1.29 (m, 2 H), 1.49 (m, 2 H),

2.48 (m, 2 H), 4.51 (s, 2 H), 6.84 (m, 1 H), 7.14 (m, 1 H), 7.30 (m, 2H), 7.42 (m, 2H), 7.65 (m, 2H), 7.97 (s, 1H), 8.46 (s, 1H).




D76

{4-Bromo-2-[1-(2-chloro-6-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}-acetic acid. Prepared from 6-bromo-3-formylchromone, 2-chloro-6-methylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.49 min, m/z 450.9 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 2.16 (s, 3H), 4.80 (s, 2H), 6.98 (d, $J = 9.1$ Hz, 1H), 7.30 (m, 1H), 7.34-7.40 (m, 2H), 7.66 (d, 1H), 7.77 (m, 1H), 8.13 (s, 1H); 8.24 (s, 1H).



D77


2-{4-Bromo-2-[1-(2,6-dimethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}-propionic acid. Prepared from 6-bromo-3-formylchromone, 2,6-dimethylphenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.55 min, m/z 440.9 $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.68(d, $J = 6.8$ Hz, 3H), 2.11 (s, 6H), 4.94 (q, $J = 7.0$ Hz 1H), 6.97 (d, $J = 8.9$ Hz, 1H), 7.19 (d, $J = 7.5$ Hz 2H), 7.28-7.32 (m, 1H), 7.63 (d, $J = 8.1$ Hz, 1H), 7.75 (m, 1H), 8.05 (s, 1H), 8.22 (s, 1H).



D78

2-{4-Bromo-2-[1-(2,6-diethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}propionic acid. Prepared from 6-bromo-3-formylchromone, 2,6-diethylphenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.85 min, m/z 469.0 $[M - H]^+$; 1H NMR ($CDCl_3$): δ 1.08-1.21 (m, 6H), 1.69-1.76 (m, 3H), 2.18-2.48 (m, 4H), 2.67 (s, 1H), 4.97 (q, $J = 6.8$ Hz 1H), 6.84 (d, $J = 9.0$ Hz, 1H), 7.00


(d, $J = 9.0$ Hz, 1H), 7.24 (d, $J = 7.7$ Hz, 1H), 7.42 (d, $J = 8.1$ Hz, 1H), 7.65 (d, $J = 9.0$ Hz, 1H), 7.77 (s, 1H), 7.86 (s, 1H), 8.06 (s, 1H), 8.22 (s, 1H).



D79


2-{4-Bromo-2-[1-(2-isopropylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}-propionic acid. Prepared from 6-bromo-3-formylchromone, 2,6-diethyl-phenylhydrazine and ethyl 2-bromopropionate according to GP1, GP2 and GP3:

LC/MS (an10p8): Rt 2.54 min, m/z 459.0 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 1.19-1.27 (m, 7H), 1.67 (d, $J = 7.0$ Hz, 2H), 4.92 (q, $J = 6.8$ Hz, 1H), 6.96 (d, $J = 8.9$ Hz, 1H), 7.27-7.53 (m, 4H), 7.58-7.67 (m, 1H), 7.73 (s, 1H), 8.17 (s, 1H), 8.20 (s, 1H).




D80

{4-Bromo-2-[1-(3,5-dichloropyridin-4-yl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid. Prepared from 6-bromo-3-formylchromone, 2,6-dichloropyridine-4-hydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.08 min, m/z 469.8 $[M - H]^-$; 1H NMR ($DMSO-d_6$): δ 4.75 (s, 2H), 7.05 (d, $J = 9.1$ Hz, 1H), 7.56 (s, 1H), 7.64 (d, $J = 9.1$ Hz, 1H), 8.32 (s, 1H), 8.77 (s, 1H), 8.93 (s, 2H).




D81


{4-Bromo-2-[1-(4-trifluoromethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid. Prepared from 6-bromo-3-formylchromone, 4-trifluoromethylphenylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10n8): Rt 2.88 min, m/z 468.9 $[M - H]^-$; 1H NMR ($CDCl_3$): δ 4.78 (s, 2H), 6.92 (d, $J = 8.9$ Hz, 1H), 7.65 (d, $J = 8.9$ Hz, 1H), 7.71 (s, 1H), 7.79 (d, $J = 8.9$ Hz, 2H), 7.91 (d, $J = 8.9$ Hz, 2H), 8.23 (s, 1H), 8.65 (s, 1H).

**D82****[4-Bromo-2-(1-naphthalen-1-yl)-1H-pyrazole-4-carbonyl]phenoxy]acetic acid.**


Prepared from 6-bromo-3-formylchromone, 1-naphthylhydrazine and ethyl bromoacetate according to GP1, GP2 and GP3: LC/MS (an10p8): Rt 2.649 min, m/z 451.0 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.78 (s, 2H), 6.93 (d, $J = 8.85$ Hz, 1H), 7.52-7.68 (m, 6H), 7.73-7.82 (m, 2H), 7.93-8.05 (m, 2H), 8.33 (s, 1H), 8.38 (s, 1H).

General synthetic route IV**General procedure 5 (GP5):**


A mixture of ethyl 2-(2-bromoacetyl)phenoxyacetate (0.1 mmol) and amide ($X = O$) or thioamide ($X = S$) (2.5 mmol) was heated neat in the microwave for 3 hours at 140 °C. After cooling, the solid residue was partitioned between EtOAc and saturated aq. $NaHCO_3$. The phases were separated and the organic phase was dried ($MgSO_4$) and concentrated *in vacuo*. The crude solid was purified by flash chromatography to give the corresponding oxazole or thiazole derivative.

**Intermediate-9**


(2-Acetyl-4-bromophenoxy)acetic acid ethyl ester Prepared from 5'-bromo-2'-hydroxyacetophenone (2 g, 9.3 mmol) and ethyl bromoacetate (1.03 mL, 9.3 mmol) according to GP2 to give the title compound as a white solid (2.64 g, 8.7 mmol, 94%): LC/MS (an10p8) Rt 3.3 min, m/z 301 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 1.32 (t, 3H), 2.71 (s, 3H), 4.30 (q, 2H), 4.72 (s, 2H), 6.76 (d, 1H), 7.55 (dd, 1H), 7.88 (s, 1H).

**Intermediate-10**


[4-Bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester. To a cooled (0 °C) solution of (2-acetyl-4-bromophenoxy)acetic acid ethyl ester (2.5 g, 8.3 mmol) in CHCl_3 (25 mL) was slowly added bromine (425 μL , 8.3 mmol). After completion the reaction mixture was allowed to stir at room temperature for 1 hour. The mixture was partitioned between CH_2Cl_2 and brine. The organic phase was washed with brine, dried (MgSO_4) and concentrated *in vacuo* to give the title compound as a white solid (2.97 g, 7.8 mmol, 94%): ^1H NMR (CDCl_3): δ 1.35 (t, 3H), 4.32 (q, 2H), 4.75 (s, 2H), 4.76 (s, 2H), 6.77 (d, 1H), 7.60 (dd, 1H), 7.97 (s, 1H)



[4-Bromo-2-(2-phenyloxazol-4-yl)phenoxy]acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and benzamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.6 min, m/z 374/376 [$\text{M} + \text{H}$] $^+$.




[4-Bromo-2-[2-(4-methoxyphenyl)oxazol-4-yl]phenoxy]acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 4-methoxybenzamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.61 min, m/z 404 [$\text{M} + \text{H}$] $^+$.




[4-Bromo-2-[2-(4-chlorophenyl)oxazol-4-yl]phenoxy]acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 4-chlorobenzamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.90 min, m/z


407.7 [M + H]⁺; ¹H NMR (CDCl₃): δ 4.89 (s, 2H), 7.09 (d, 1H), 7.48 (d, 1H), 7.64 (d, 2H), 8.08 (d, 2H), 8.20 (s, 1H), 8.89 (s, 1H), 13.2 (br s, 1H).

**D86**


{4-Bromo-2-[2-(3-methoxyphenyl)oxazol-4-yl]phenoxy}acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 3-methoxybenzamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.68 min, *m/z* 404 [M + H]⁺; ¹H NMR (CDCl₃): δ 3.87 (s, 1H), 4.89 (s, 2H), 7.09 (m, 2H), 7.4-7.7 (m, 4H), 8.22 (s, 1H), 8.89 (s, 1H), 13.3 (br s, 1H).

**D87**


{4-Bromo-2-[2-(4-ethoxyphenyl)oxazol-4-yl]phenoxy}acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 4-ethylbenzamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.80 min, *m/z* 418/420 [M + H]⁺; ¹H NMR (CDCl₃): δ 1.36 (t, 3H), 4.10 (q, 2H), 4.88 (s, 2H), 7.07 (m, 3H), 7.47 (d, 1H), 8.00 (d, 2H), 8.20 (s, 1H), 8.82 (s, 1H), 13.4 (br s, 1H).

**D88**


[2-(2-Benzylloxazol-4-yl)-4-bromophenoxy]acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 2-phenylacetamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.47 min, *m/z* 388 [M + H]⁺; ¹H NMR (CDCl₃): δ 4.22 (s, 2H), 4.84 (s, 2H), 7.04 (d, 1H), 7.25 (m, 5H), 7.43 (d, 1H), 8.06 (s, 1H), 8.69 (s, 1H), 13 (br s, 1H).

**D89**


{4-Bromo-2-[2-(3-methoxybenzyl)oxazol-4-yl]phenoxy}acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 2-(3-methoxyphenyl)acetamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.45 min, m/z 418 $[M + H]^+$.

**D90**


{4-Bromo-2-[2-(2-chloro-4-fluorobenzyl)oxazol-4-yl]phenoxy}acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 2-(2-chloro-4-fluorophenyl)acetamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.75 min, m/z 440 $[M + H]^+$.

**D91**

{4-Bromo-2-[2-(2,6-dichlorobenzyl)oxazol-4-yl]phenoxy}acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 2-(2,6-dichlorophenyl)acetamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.75 min, m/z 456/458/460 $[M + H]^+$.


**D92**

{4-Bromo-2-[2-(4-methoxybenzyl)oxazol-4-yl]phenoxy}acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 2-(4-methoxyphenyl)acetamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.40 min, m/z 418 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 3.72 (s, 3H), 4.14 (s, 1H), 4.85 (s, 1H), 6.92 (m, 2H), 7.02 (d, 1H), 7.2 (d, 1H), 7.23 (d, 1H), 7.44 (d, 1H), 8.05 (s, 1H), 8.67 (s, 1H), 13.2 (br s, 1H).



D93


[4-Bromo-2-(2-phenylthiazol-4-yl)phenoxy]acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and thioacetamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.69 min, m/z 390 $[M + H]^+$.



D94

{4-Bromo-2-[2-(4-chlorobenzyl)thiazol-4-yl]phenoxy}acetic acid Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and 2-(4-chlorophenyl)thioacetamide according to GP5 and GP3: LC/MS (an10p8) Rt 2.69 min, m/z 390 $[M + H]^+$; 1H NMR ($CDCl_3$): δ 4.42 (s, 2H), 4.86 (s, 2H), 7.06 (d, 1H), 7.45 (m, 5H), 8.33 (s, 1H), 8.41 (s, 1H), 13.2 (br s, 1H).

General synthetic route V




General procedure 6 (GP6)

Synthesis of carbonylthiazoles


A mixture of the thioamide (1.0 mmol) and N,N-dimethylformamide dimethylacetal (1.2 mmol) was stirred for 1 hour at room temperature under argon. The volatile materials were removed under reduced pressure without heating to give the corresponding N'-thioaroylformamidine which was used without further purification in the next step.

To a solution of the ethyl 2-(2-bromoacetyl)phenoxyacetate (1 mmol) and the N'-thioaroylformamidine (1 mmol) in benzene (2.6 mL) was added an excess of triethylamine (5 mmol). After stirring overnight at room temperature, solvent was removed *in vacuo*. The residue was partitioned between EtOAc and saturated aq. NaHCO₃. The organic phase was dried (MgSO₄) and concentrated *in vacuo*. The crude material was purified by flash chromatography to give the thioamide.

**D95**

[4-Bromo-2-(2-phenylthiazole-5-carbonyl)phenoxy]acetic acid. Title compound was prepared from [4-bromo-2-(2-bromoacetyl)phenoxy]acetic acid ethyl ester and thiobenzamide according to GP6 and GP3: LC/MS (an10p8) Rt 2.44 min, *m/z* 418 [M + H]⁺.

General synthetic route VI



General procedure 7 (GP7)


Synthesis of oxazole

A mixture of benzamide (1.0 mmol) and 2-bromoacetophenone (0.5 mmol) was heated neat in an Emrys Optimizer microwave oven for 3 hours at 140 °C. After cooling EtOAc and CH₂Cl₂ were added and the formed precipitate was filtered off. The filtrate was concentrated *in vacuo* and purified by flash chromatography to give the corresponding oxazole.

**Intermediate-11**


(4-Bromo-2-carbamoylphenoxy)acetic acid ethyl ester. Prepared from bromosalicylamide and ethyl bromoacetate according GP2: ¹H NMR (CDCl₃): δ 1.35

(t, 3H), 4.34 (q, 2H), 4.73 (s, 2H), 5.87 (br s, 1H), 6.76 (d, 1H), 7.56 (d, 1H), 8.33 (br s, 1H), 8.39 (s, 1H).



[4-Bromo-2-(4-phenyl-oxazol-2-yl)-phenoxy]acetic acid. Title compound was prepared from (4-bromo-2-carbamoylphenoxy)acetic acid ethyl ester and 2-bromoacetophenone according to GP7: LC/MS (an10p8) Rt 2.32 min, m/z 374/376 $[M + H]^+$.

General synthetic route VII



General procedure 8 (GP8):

Synthesis of hydroxamic acid chloride

To a solution of the aldoxime (1.0 mmol) in CH_2Cl_2 (1.7 mL) was added N-chlorosuccinimide (1.0 mmol) in one portion. The reaction mixture was stirred for 3 hours at room temperature under an argon atmosphere. Water was added. The phases were separated. The organic phase was dried (MgSO_4) and concentrated *in vacuo* to give the corresponding hydroxamic acid chloride derivative which was used without further purification.


General procedure 9 (GP9):

Synthesis of isoxazole

To a solution of the hydroxamic acid chloride (1.0 mmol) and (4-bromo-2-propynoyl-phenoxy)acetic acid ethyl ester (1.0 mmol) in dry CH_2Cl_2 (3.7 mL) was slowly added a solution of Et_3N (1.0 mmol) in dry CH_2Cl_2 (0.6 mL) over a period of 4 hours (use of syringe-pump). After completion of the addition, the reaction mixture was washed

with water, brine, dried (MgSO_4) and concentrated *in vacuo*. The crude oil was purified by flash chromatography to give the corresponding isoxazol derivative.

Synthesis of Intermediate-12




(4-Bromo-2-formylphenoxy)acetic acid ethyl ester. Prepared from 5-bromo-2-hydroxybenzaldehyde according GP2: LC/MS (an10p8) Rt 3.45min, m/z 287 $[\text{M} + \text{H}]^+$; ^1H NMR (CDCl_3): δ 1.29 (t, 3H), 4.25 (q, 2H), 4.74 (s, 2H), 6.79 (d, 1H), 7.60 (d, 1H), 7.94 (s, 1H), 10.46 (s, 1H)

[4-Bromo-2-(1-hydroxy-3-trimethylsilylprop-2-ynyl)phenoxy]acetic acid ethyl ester. To a cooled (-78°C) solution of (trimethylsilyl)acetylene (3.93 g, 40.0 mmol) in dry THF (40 mL) was slowly added a 2.5 M solution of butyllithium in hexanes (14.54 mL, 36.36 mmol). After stirring for 30 minutes at -78°C , the mixture was transferred to a cooled (-78°C) solution of (4-bromo-2-formylphenoxy)acetic acid ethyl ester (10.44 g, 36.36 mmol) in dry THF (120 mL). Upon completion, the reaction mixture was stirred at -78°C for 45 minutes. Saturated aq. NH_4Cl (40 mL) was slowly added to the reaction mixture followed by Et_2O (40 mL). The quenched reaction mixture was allowed to warm up to room temperature. The phases were separated and the aqueous phase was extracted with Et_2O (2x). The combined organic phases were washed with brine, dried (MgSO_4) and concentrated *in vacuo*. The crude oil was purified by column chromatography (SiO_2), then was stirred for 90 min with polystyrene-supported trisamine (PS-Trisamine, 4.17 mmol/g, 8 g) in CH_2Cl_2 (160 mL). The resin was filtered off and the filtrate was concentrated *in vacuo* to give the title compound as pale yellow oil (7.6 g, 19.7 mmol, 54%). LC/MS (an10p8) Rt 4.30min, m/z 408 $[\text{M} + \text{Na}]^+$; ^1H NMR (CDCl_3): δ 0.24 (s, 9H), 1.31 (t, 3H), 4.27 (q, 2H), 4.71 (s, 2H), 5.79 (s, 1H), 6.74 (d, 1H), 7.39 (dd, 1H), 7.79 (d, 1H).


[4-Bromo-2-(3-trimethylsilylpropynoyl)phenoxy]acetic acid ethyl ester. To a solution of [4-bromo-2-(1-hydroxy-3-trimethylsilylprop-2-ynyl)phenoxy]acetic acid

ethyl ester (0.95 g, 2.46 mmol) in CH_2Cl_2 (10 mL) was added activated MnO_2 in 2 portions (1.5 g + 1 g), and the reaction was stirred for 90 min. The solid was filtered off through a celite pad and the filtrate was concentrated *in vacuo* to give the title compound as yellow oil (0.83 g, 2.16 mmol, 87%). LC/MS (an10p8) Rt 4.70min, m/z 383 $[\text{M} + \text{H}]^+$; ^1H NMR (CDCl_3): δ 0.30 (s, 9H), 1.30 (t, 3H), 4.27 (q, 2H), 4.72 (s, 2H), 6.81 (d, 1H), 7.58 (dd, 1H), 8.10 (s, 1H).


(4-Bromo-2-propynoylphenoxy)acetic acid ethyl ester. To a solution of [4-bromo-2-(3-trimethylsilanylpropynoyl)phenoxy]acetic acid ethyl ester (0.83 g, 2.16 mmol) in methanol (20 mL) was added a 0.1M aqueous solution of $\text{Na}_2\text{B}_4\text{O}_7$ (10 mL). After stirring for 2 – 3 minutes at room temperature, Et_2O and 1N aq. HCl were added. The phases were separated, and the organic phase was washed with brine, dried (MgSO_4) and concentrated *in vacuo* to give the title compound as yellow oil which crystallized upon standing (0.65 g, 2.09 mmol, 96%). LC/MS (an10p8) Rt 3.58min, m/z 311 $[\text{M} + \text{H}]^+$; ^1H NMR (CDCl_3): δ 1.31 (t, 3H), 3.45 (s, 1H), 4.27 (q, 2H), 4.74 (s, 2H), 6.83 (d, 1H), 7.61 (dd, 1H), 8.14 (d, 1H).



[4-Bromo-2-(3-phenylisoxazole-5-carbonyl)phenoxy]acetic acid Title compound was prepared from benzalddoxime and (4-bromo-2-propynoylphenoxy)acetic acid ethyl ester according to GP8 and GP9: LC/MS (an10n8) Rt 3.07 min, m/z 400 $[\text{M} - \text{H}]^-$; ^1H NMR (DMSO): δ 4.77 (s, 2H), 7.13 (d, 1H), 7.53 (m, 3H), 7.73-7.92 (m, 5H).




{4-Bromo-2-[3-(2,6-dichloro-phenyl)isoxazole-5-carbonyl]phenoxy}acetic acid. Title compound was prepared from 2,6-dichlorobenzalddoxime and (4-bromo-2-propynoylphenoxy)acetic acid ethyl ester according to GP8 and GP9: LC/MS (an10n8) Rt 2.74 min, m/z 471.9 $[\text{M} + \text{H}]^+$.

General Synthetic Route VIII**General procedure 10 (GP10)**Synthesis of amidoximes


Sodium (1.25 mmol) was added to dry methanol (1ml) to give solution A. Hydroxylamine hydrochloride (1.2 mmol) was dissolved in dry methanol (1mL) to give solution B. Solution A and B were mixed, cooled in an ice-bath and filtered. To the filtrate was then added the nitrile (1 mmol) and the reaction mixture was stirred over night at room temperature. The solvent was removed *in vacuo* to give the corresponding amidoxime. The compound was purified over silica gel chromatography (EtOAc/Heptane: 1/2) or used without further purification.

General procedure 11 (GP11)Synthesis of oxadiazoles


To a solution of sodium (3.3 mmol) in dry ethanol (10 mL) were successively added the amidoxime (1.15 mmol), molecular sieves (1g) and methyl benzoate (1 mmol). After stirring for 12 h under reflux, the reaction mixture was cooled and filtered through a celite pad. The celite pad was washed with methanol and CH_2Cl_2 . The solvent was removed *in vacuo* and the residue was stirred with water. The precipitate was filtered off and dried to give the corresponding oxadiazole. The compound was purified over silica gel chromatography (EtOAc:Heptane, 1:2) or used without further purification in.

**D99**

[4-Bromo-2-(3-phenyl-[1,2,4]oxadiazol-5-yl)phenoxy]acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and benzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8): Rt 2.41 min, m/z 373.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.97 (s, 2H), 7.2 (d, 1H), 7.62 (s, 3H), 7.82 (d, 2H), 8.10 (d, 1H), 8.2 (s, 1 H).

**D100**


{4-Bromo-2-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 4-fluorobenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.49, m/z 391.4 $[M - H]^-$.

**D101**


{4-Bromo-2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 4-methoxybenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.44 min, m/z 403.4 $[M - H]^-$.

**D102**

{4-Bromo-2-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 4-chlorobenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.68 min, m/z 407.4 $[M - H]^-$.


**D103**

{4-Bromo-2-[3-(4-trifluoromethoxyphenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 4-trifluoromethoxybenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.09 min, m/z 457.5 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.96 (s, 2H), 7.21 (d, 1H), 7.59 (d, 2H), 7.82 (d, 1H), 8.22 (d, 3H).

**D104**

{4-Bromo-2-[3-(3-methoxyphenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid.


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 3-methoxybenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.47 min, m/z 403.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 3.86 (s, 3H), 4.96 (s, 2H), 7.20 (d, 2H), 7.5 (t, 1H), 7.6 (s, 1H), 7.67 (d, 1H), 7.8 (d, 1H), 8.2 (s, 1H).

**D105**


{4-Bromo-2-[3-(3-chlorophenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid. Title

compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 3-chlorobenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.69


min, m/z 407.4 $[M - H]^-$; 1H NMR (DMSO): δ 4.97 (s, 2H), 7.2 (d, 1H), 7.6 (m, 2H), 7.7 (d, 1H), 7.8 (d 2 H), 8.2, (s, 1H).

**D106****{4-Bromo-2-[3-(4-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}-acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 4-trifluoromethylbenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.83 min, m/z 441.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.97 (s, 2H), 7.2 (d, 1H), 7.8 (dd, 1H), 7.9 (d, 2H), 8.2 (d, 1H), 8.3 (d, 2H).

**D107****{4-Bromo-2-[3-(2-methoxyphenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 2-methoxybenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.31 min, m/z 403.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 2.5 (s, 3H), 4.94 (s, 2H), 7.2 (m, 3H), 7.5 (t, 1H), 7.7 (d, 1H), 7.9 (d, 1H), 8.1 (s, 1H).

**D108**


{4-Bromo-2-[3-(2-chlorophenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 2-chlorobenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.50 min, m/z 407.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.94 (s, 2H), 7.2 (d, 1H), 7.5-7.7 (m, 3H), 7.8 (dd, 1H), 8.0 (d, 1H), 8.1 (s, 1H).

**D109**


{2-[3-(3,5-Bis-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-4-bromo-phenoxy}-acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 3,5-bistrifluoromethoxybenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 3,332 min, m/z 509.5 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.96 (s, 2H), 7.2 (d, 1H), 7.8 (d, 1H), 8.2 (s, 1H), 8.4 (s, 1H), 8.5 (s, 1H), 8.6 (s, 1H).

**D110**


{4-Bromo-2-[3-(2,6-dichlorophenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 2,6-Dichloro-benzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.59 min, m/z 441.4 $[M - H]^-$.

**D111**


{4-Bromo-2-[3-(4-phenoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 4-phenoxybenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 3.29 min, m/z 465.5 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.95 (s, 2H), 7.2 (m, 6H), 7.4 (t, 2H), 7.8 (d, 1H), 8.0 (d, 2H), 8.1 (s, 1H).

**D112****{4-Bromo-2-[3-(3-trifluoromethylphenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}-acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 3-trifluoromethylbenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.96 min, m/z 441.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.97 (s, 2H), 7.2 (d, 1H), 7.8 (m, 2H), 8.0 (d, 1H), 8.2 (s, 1H), 8.3 (s, 1H), 8.4 (d, 1H).

**D113****{4-Bromo-2-[3-(4-trifluoromethoxybenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}-acetic acid.**

Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (4-trifluoromethoxyphenyl) acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.76 min, m/z 4715 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.2 (s, 2H), 4.9 (s, 2H), 7.1 (d, 1H), 7.3 (d, 2H), 7.5 (d, 2H), 7.7 (d, 1H), 8.0 (s, 1H).


**D114****{4-Bromo-2-[3-(4-chlorobenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}-acetic acid.**

Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (4-chlorophenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.54 min, m/z 421.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.2 (s, 2H), 4.9 (s, 2H), 7.1 (d, 1H), 7.4 (s, 4H), 7.8 (d, 1H), 8.0 (s, 1H).


**D115**

[2-(3-Benzyl-[1,2,4]oxadiazol-5-yl)-4-bromo-phenoxy]-acetic acid. Title


compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and phenylacetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.26 min, m/z 387.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.2 (s, 2H), 4.9 (s, 2H), 7.1 (d, 1H), 7.3 (m, 5H), 7.7 (d, 1H), 8.0 (s, 1H).

**D116****{4-Bromo-2-[3-(4-fluoro-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid.** Title


compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (4-fluorophenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.38 min, m/z 405.4 $[M - H]^-$.

**D117****{4-Bromo-2-[3-(3,5-difluoro-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (3,5-difluorophenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.44 min, m/z 423.4 $[M - H]^-$.

**D118****{4-Bromo-2-[3-(4-methoxy-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (4-methoxyphenyl) acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.25 min, m/z 417.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.1 (s, 2H), 4.9 (s, 2H), 6.9 (d, 2H), 7.1 (d, 1H), 7.2 (d, 2H), 7.7 (d, 1H), 8.0 (s, 1H).

**D119****{4-Bromo-2-[3-(2-methoxy-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (2-Methoxy-phenyl)-acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.25 min, m/z 417.4 [M - H]⁻; ¹H NMR (DMSO-d₆): δ 3.7 (s, 3H), 4.1 (s, 2H), 4.9 (s, 2H), 6.9 (t, 1H), 7.0 (d, 1H), 7.1 (d, 1H), 7.2 (m, 2H), 7.7 (d, 1H), 8.0 (s, 1H).

**D120****{4-Bromo-2-[3-(2-chloro-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (2-chlorophenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.48 min, m/z 421.4 [M - H]⁻; ¹H NMR (DMSO-d₆): δ 4.2 (s, 2H), 4.9 (s, 2H), 7.1 (d, 1H), 7.3 (m, 2H), 7.4 (m, 2H), 7.7 (dd, 1H), 8.0 (d, 1H).

**D121****{4-Bromo-2-[3-(2,6-dichloro-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (2,6-dichlorophenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.58 min, m/z 455/457/459 [M - H]⁻; ¹H NMR (DMSO-d₆): δ 4.4 (s, 2H), 4.9 (s, 2H), 7.1 (d, 1H), 7.4 (t, 1H), 7.5 (d, 2H), 8.7-7.8 (dd, 1H), 8.0 (d, 1H).

**D122****{4-Bromo-2-[3-(2,4-dichloro-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (2,4-dichlorophenyl) acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2,78 min, m/z 455/457/459 $[M - H]^-$.

**D123****{4-Bromo-2-[3-(3,4-dichlorobenzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (3,4-dichlorophenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.81 min, m/z 455/457/459 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.3 (s, 2H), 4.8 (s, 2H), 7.1 (d, 1H), 7.3 (dd, 1H), 7.6 (d, 1H), 7.6 (d, 1H), 7.7 (dd, 1H), 8.0 (d, 1H).

**D124****{4-Bromo-2-[3-(3,4-dimethoxybenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}-acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (3,4-bismethoxyphenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.20 min, m/z 447,4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 3.72 (s, 3H), 3.74 (s, 3H), 4.1 (s, 2H), 4.9 (s, 2H), 6.8 (m, 2H), 6.9 (s, 1H), 7.1 (d, 1H), 7.7 (dd, 1H), 8.0 (d, 1H).

**D125****{4-Bromo-2-[3-(3-methoxybenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (3-methoxyphenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.38 min, m/z 417.4 [M - H]⁻; ¹H NMR (DMSO-d₆): δ 4.1 (s, 2H), 4.9 (s, 2H), 6.8 (d, 1H), 6.9 (m, 2H), 7.1 (d, 1H), 7.2 (t, 1H), 7.8 (m, 1H), 8.0 (d, 1H).

**D126**


{4-Bromo-2-[3-(4-methylbenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (4-methylphenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.72 min, m/z 401.4 [M - H]⁻; ¹H NMR (DMSO-d₆): δ 3.3 (s, 3H), 4.1 (s, 2H), 4.9 (s, 2H), 7.1 (m, 3H), 7.2 (d, 2H), 7.7 (dd, 1H), 8.0 (d, 1H).

**D127**


{4-Bromo-2-[3-(2-trifluoromethylbenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (2-trifluoromethylphenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.77 min, m/z 455.5 [M - H]⁻; ¹H NMR (DMSO-d₆): δ 4.3 (s, 2H), 4.9 (s, 2H), 7.1 (d, 1H), 7.5-7.6 (m, 2H), 7.6-7.7 (t, 1H), 7.7-7.8 (m, 2H), 8.0 (d, 1H).

**D128****{4-Bromo-2-[3-(3,5-dimethoxybenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid.**


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and (3,5-bismethoxyphenyl)acetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.61 min, m/z 447.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 3.7 (s, 6H), 4.1 (s, 2H), 4.9 (s, 2H), 6.4 (d, 1H), 6.5 (d, 2H), 7.1 (d, 1H), 7.8 (dd, 1H), 8.0 (d, 1H).

**D129****{4-Bromo-2-[3-(2,4-dichlorophenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid.**

Title compound was prepared from 5-bromo-2-hydroxy-benzoic acid methyl ester and 2,4-dichlorobenzonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.93 m/z 441/443/445 $[M - H]^-$; 1H NMR (DMSO): δ 4.7 (s, 1H), 6.95-6.98 (d, 1H), 7.42-7.44 (d, 1H), 7.58-7.60 (d, 1H), 7.67 (s, 1H), 7.82-7.85 (d, 1H), 7.94-7.95 (s, 1H).


**D130****{4-Bromo-2-[3-(3-chlorobenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid.**

Title compound was prepared from 5-bromo-2-hydroxy-benzoic acid methyl ester and 3-chlorophenylacetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.79 m/z 421.4 $[M - H]^-$; 1H NMR (DMSO): δ 4.21 (s, 2H), 4.92 (s, 2H), 7.15-7.18 (d, 1H), 7.32-7.39 (m, 3H), 7.45 (s, 1H), 7.76-7.80 (dd, 1H), 8.03-8.04 (d, 1H).


**D131**

{2-[3-(4-Acetylamino benzyl)-[1,2,4]oxadiazol-5-yl]-4-bromophenoxy}acetic acid.


Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and 4-acetamidophenylacetonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.15 *m/z* 444.4 [M – H][–]; ¹H NMR (DMSO): δ 2.02 (s, 3H), 4.10 (s, 2H), 4.92 (s, 2H), 7.14-7.17(d, 1H), 7.25-7.27(d, 2H), 7.52-7.54 (d, 2H), 7.76-7.78 (d, 1H), 8.03 (s, 1H).


**D132****{4-Bromo-2-[3-(1-phenylcyclopropyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid.**

Title compound was prepared from 5-bromo-2-hydroxy-benzoic acid methyl ester and 1-phenyl-1-cyclopropanecarbonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt.2.756 *m/z* 413.4 [M – H][–]; ¹H NMR (DMSO-d₆): δ 0.92 (m, 2H), 1.11 (m, 2H), 4.38 (s, 2H), 6.63-6.66 (d, 1H), 6.79-6.88 (m, 3H), 6.93-6.95 (m, 2H), 7.25-7.29 (dd, 1H), 7.50-7.51 (d, 1H).


**D133**

[4-Bromo-2-(3-pyridin-2-yl-[1,2,4]oxadiazol-5-yl)phenoxy]acetic acid. Title compound was prepared from 5-bromo-2-hydroxybenzoic acid methyl ester and Pyridine-2-carbonitrile according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 1.89 min, *m/z* 374.4 [M – H][–]; ¹H NMR (DMSO-d₆): δ 4.9 (s, 2H), 7.2 (d, 1H), 7.6 (m, 1H), 7.8 (d, 1H), 8.0 (t, 1H), 8.2 (m, 2H), 8.8 (d, 1H).


General Synthetic route IX

**D134**


{4-Bromo-2-[5-(4'-methoxybiphenyl-4-yl)-[1,2,4]oxadiazol-3-yl]phenoxy}acetic acid. Title compound was prepared from 2-hydroxy-5-bromo-benzonitrile and 4'-methoxy-biphenyl-4-carboxylic acid methyl ester according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.96 min, m/z 479.5 $[M - H]^-$.

**D135**

{4-Bromo-2-[5-(4-chlorophenyl)-[1,2,4]oxadiazol-3-yl]phenoxy}acetic acid. Title compound was prepared from 2-hydroxy-5-bromo-benzonitrile and 4-chlorobenzoic acid methyl ester according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.61 min, m/z 407.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.3 (s, 2H), 6.9 (d, 1H), 7.6 (dd, 1H), 7.7 (d, 2H), 8.0 (d, 1H), 8.2 (d, 2H).


**D136**

{4-Bromo-2-[5-(3-chlorophenyl)-[1,2,4]oxadiazol-3-yl]phenoxy}acetic acid. Title compound was prepared from 2-hydroxy-5-bromobenzonitrile and 3-chlorobenzoic acid methyl ester according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.61 min, m/z 407.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.4 (s, 2H), 6.9 (d, 1H), 7.6 (m, 2H), 7.8 (d, 1H), 8.0 (s, 1H), 8.2 (m, 2H).

**D137**

{4-Bromo-2-[5-(2-chlorophenyl)-[1,2,4]oxadiazol-3-yl]phenoxy}acetic acid. Title compound was prepared from 2-hydroxy-5-bromobenzonitrile and 2-chlorobenzoic acid methyl ester according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.45



min, m/z 407.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.3 (s, 2H), 6.9 (d, 1H) 7.6-7.7 (m, 4H), 8.0 (s, 1H), 8.2 (d, 1H).



D138

[4-Bromo-2-(5-phenyl-[1,2,4]oxadiazol-3-yl)phenoxy]acetic acid. Title compound was prepared from 2-hydroxy-5-bromobenzonitrile and benzoic acid methyl ester according to GP10, GP11, GP2 and GP3: LC/MS (an10n8) Rt 2.33 min, m/z 373.4 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 4.8 (s, 2H), 7.1 (d, 1H), 7.6-7.7 (m, 4H), 8.0 (d, 1H), 8.2 (d, 2H).

General Synthetic Route X




Intermediate-13


4-Bromo-2-[(ethoxycarbonylmethylamino)methyl]phenoxyacetic acid ethyl ester. 4-Bromo-2-formylphenoxyacetic acid ethyl ester (1.44 g, 5 mmol) was dissolved in dichloromethane (50 mL) and glycine ethyl ester hydrochloride (1.39 g, 10 mmol) as well as Et_3N (1.4 mL, 10 mmol) was added. The mixture was stirred at room temperature for 4 h. Water and dichloromethane was added and the organic phase was passed through a phase separation filter and then evaporated to give {4-bromo-2-[(E)-ethoxycarbonylmethyliminomethyl]phenoxy}acetic acid ethyl ester, which was redissolved in dichloromethane (50 mL) and treated with $NaBH(OAc)_3$ (2.11 g, 10 mmol) and AcOH (1 mL), and then stirred at room temperature for 5 h. Saturated Na_2CO_3 , water and dichloromethane was added, and the organic phase was passed through a phase separation filter and evaporated to give the title compound (1.56 g, 84% overall yield).

General procedure 12 (GP12)Reaction with isocyanates followed by ringclosure/hydrolysis

The aldehyde (0.6 mmol) was dissolved in dichloromethane (6 mL), and the isocyanate (1.2 mmol) and Et₃N (176 μ L, 1.26 mmol) was added. The mixture was stirred at room temperature overnight. Then glycine (150 mg, 2 mmol) was added (as scavenger for excess isocyanate) and the mixture was stirred for additional 2 h. Finally water and dichloromethane was added and the organic phase was passed through a phase separation filter and then evaporated to give the urea, which was dissolved in acetic acid (3.5 mL) and placed in a sealed glass vial. Then 4 M HCl (3.5 mL) was added and the mixture heated by microwaves to 100 °C for 900s. After cooling to room temperature a white precipitate was formed, and the hydantoin was obtained after filtration and washing with water. In cases where the product did not precipitate after the hydrolysis, dichloromethane and water was added to the mixture, and the organic phase was passed through a phase separation filter. Evaporation of the organic phase gave the product, which in some cases was further purified on a 1 g SAX Acetate SPE column (equilibrated with 100% MeOH and then eluted with 10% AcOH in MeOH).

**D139**

4-Bromo-2-[3-(4-chlorobenzyl)-2,4-dioxoimidazolidin-1-ylmethyl]phenoxyacetic acid. Prepared from 4-bromo-2-[(ethoxycarbonylmethylamino)methyl]phenoxyacetic acid ethyl ester (235 mg, 0.63 mmol) and 4-chlorobenzylisocyanate (166 μ L, 1.26 mmol) according to GP12 (yield: 183.4 mg, 62%): LC/MS (an10p8): Rt 2.3 min, m/z 465 [M - H]⁻; ¹H NMR (DMSO-*d*₆): δ 4.05 (s, 2H), 4.48 (s, 2H), 4.55 (s, 2H), 4.73 (s, 2H), 6.92 (d, J = 8.3 Hz, 1H), 7.25-7.45 (m, 6H), 13.11 (br. s, 1H).


**D140**

4-Bromo-2-(2,4-dioxo-3-phenethylimidazolidin-1-ylmethyl)phenoxyacetic acid.

Prepared from 4-bromo-2-[(ethoxycarbonylmethylamino)methyl]phenoxyacetic acid ethyl ester and phenethylisocyanate according to GP12: LC/MS (an10p8): Rt 2.2 min,

m/z 445 $[M - H]^-$; 1H NMR (DMSO- d_6): δ 2.84 (t, $J = 7.2$ Hz, 2H), 3.59 (t, $J = 7.2$ Hz, 2H), 3.94 (s, 2H), 4.45 (s, 2H), 4.76 (s, 2H), 6.93 (d, $J = 8.6$ Hz, 1H), 7.17-7.46 (m, 7H), 12.45 (br. s, 1H).

General Synthetic Route XI



General procedure 13 (GP13)

N-Alkylation

The 2-[2,4-dioxothiazolidin-(5Z)-ylidenemethyl]phenoxyacetic acid ethyl ester (0.85 mmol), Cs_2CO_3 (326 mg, 1.0 mmol), and acetonitrile (10 mL) was mixed in a sealed glass vial. Then the alkylating agent (1.0 mmol) was added and the mixture heated by microwaves to 120 °C for 600 s. Water was added and the mixture was extracted with dichloromethane. The organic phase was passed through a phase separation filter and then evaporated. The product was used directly in the next step or purified by column chromatography (SiO_2).

General procedure 14 (GP14)

Hydrogenation

The 5-benzylidenethiazolidine-2,4-dione (~0.8 mmol), ammonium formate (1.0 g, 16 mmol), Pt/C (5 wt%, 500 mg, 0.13 mmol), and acetic acid (12 mL) was mixed in a

sealed glass vial and heated by microwaves to 135 °C for 1800 s. Then methanol (15 mL) was added and the mixture was filtered through a 20 µm PE filter and then through a 1 g SAX Acetate SPE column, which was washed with additional methanol (10 mL). After evaporation of the methanol, dichloromethane and water was added, and the organic phase was passed through a phase separation filter and concentrated to give the product, which was used directly or purified by column chromatography on SiO₂.

General procedure 15 (GP15)


Alkylation of 5-position of thiazolidine-2,4-diones

3-Alkyl-5-arylthiazolidine-2,4-dione (0.15 mmol), methyl iodide (28 µL, 0.45 mmol), Cs₂CO₃ (147 mg, 0.45 mmol), and acetonitrile (10 mL) was mixed in a sealed glass vial and heated by microwaves to 120 °C for 3600 s. Water and dichloromethane was added and the organic phase was passed through a phase separation filter and then evaporated to give the product, which was used directly for the hydrolysis.

General procedure 16 (GP16)

Acidic ester hydrolysis

The ethyl phenoxyacetate (0.02-0.2 mmol) was dissolved in acetic acid (5 mL), 4M HCl (5 mL) was added and the mixture was heated by microwaves to 100 °C for 900 s. After cooling to room temperature a white precipitate was formed, which was filtered of, washed with water and dried to give the product. In cases where the product did not precipitate after the hydrolysis, dichloromethane was added, the organic phase was washed with water and concentrated, and the residue was purified on a 1 g SAX Acetate SPE column (equilibrated with 100% MeOH and then eluted with 10% AcOH in MeOH) to give the product.




Intermediate-14


4-Bromo-2-[2,4-dioxothiazolidinylidenemethyl]phenoxyacetic acid ethyl ester.

4-Bromo-2-formylphenoxyacetic acid ethyl ester (2.47 g, 8.7 mmol), 2,4-thiazolidinedione (1.13 g (90%), 8.7 mmol), and ammonium acetate (671 mg, 8.7 mmol) was mixed with toluene (9 mL) in a sealed vial and heated by microwaves to 120 °C for 600 s. After cooling to room temperature and scratching the inside of the


glass, the product precipitated out. The precipitate was filtered and washed with toluene to give the title compound as a yellow solid (2.38 g, 71%).

**D141**

4-Bromo-2-[3-(4-chlorobenzyl)-2,4-dioxothiazolidin-5-ylmethyl]phenoxyacetic acid. Prepared from 4-chlorobenzylbromide and 4-bromo-2-[2,4-dioxothiazolidin-(5Z)-ylidenemethyl]phenoxyacetic acid ethyl ester according to GP13, GP14 and GP16 to give 50.4 mg (21% overall yield) of the title compound: LC/MS (an10p8): Rt 2.6 min, m/z 482 $[M - H]^-$. 1H NMR (DMSO- d_6): δ 3.05 (dd, $J = 13.8, 9.7$ Hz, 1H), 3.57 (dd, $J = 13.8, 4.9$ Hz, 1H), 5.11 (dd, $J = 9.7, 4.9$ Hz, 1H), 4.67 (s, 2H), 4.75 (s, 2H), 6.91 (d, $J = 8.7$, 1H), 7.25-7.28 (m, 2H), 7.37-7.42 (m, 4H), 13.15 (br. s, 1H).


**D142**

4-Bromo-2-[3-(4-methylbenzyl)-2,4-dioxothiazolidin-5-ylmethyl]phenoxyacetic acid. Prepared from 4-methylbenzylbromide and 4-bromo-2-[2,4-dioxothiazolidin-(5Z)-ylidenemethyl]phenoxyacetic acid ethyl ester according to GP13, GP14 and GP16 (yield: 14 mg, 21%): LC/MS (an10p8): Rt 2.5 min, m/z 462 $[M - H]^-$. 1H NMR (DMSO- d_6): δ 2.98-3.07 (m, 1H), 3.53-3.59 (m, 1H), 4.63 (s, 2H), 4.74 (s, 2H), 5.07-5.13 (m, 1H), 6.89-6.91 (m, 1H), 7.11-7.16 (m, 4H), 7.38-7.43 (m, 2H), 13.11 (br s, 1H).


**D143**

4-Bromo-2-[3-[2-(4-chlorophenyl)-2-oxoethyl]-2,4-dioxothiazolidin-5-ylmethyl]phenoxyacetic acid. Prepared from 2-bromo-1-(4-chlorophenyl)ethanone and 4-bromo-2-[2,4-dioxothiazolidin-(5Z)-ylidenemethyl]phenoxyacetic acid ethyl ester according to GP13, GP14 and GP16 (yield: 8.2 mg, 34%): LC/MS (an10p8): Rt


2.8 min, m/z 510 $[M - H]^-$. 1H NMR (DMSO- d_6): δ 3.01-3.09 (m, 1H), 3.57-3.63 (m, 1H), 4.79 (s, 2H), 5.17 (s, 2H), 5.21-5.24 (m, 1H), 6.91-6.95 (m, 1H), 7.44 (m, 2H), 7.66-7.69 (m, 2H), 8.07-8.09 (m, 2H).




4-Bromo-2-[3-(3-chlorobenzyl)-2,4-dioxothiazolidin-5-ylmethyl]phenoxyacetic acid (7d). Prepared from 3-chlorobenzyl bromide and 4-bromo-2-[2,4-dioxothiazolidin-(5Z)-ylidenemethyl]phenoxyacetic acid ethyl ester according to GP13, GP14 and GP16: LC/MS (an10p8): Rt 2.6 min, m/z 484 $[M + H]^+$. 1H NMR (DMSO- d_6): δ 3.02-3.10 (m, 1H), 3.54-3.60 (m, 1H), 4.69 (s, 2H), 4.75 (s, 2H), 5.09-5.14 (m, 1H), 6.89-6.92 (m, 1H), 7.18 (m, 1H), 7.33-7.43 (m, 5H), 13.01 (br s, 1H).



4-Bromo-2-(2,4-dioxo-3-pyridin-4-ylmethylthiazolidin-5-ylmethyl)phenoxyacetic acid. Prepared from 4-bromomethylpyridine and 4-bromo-2-[2,4-dioxothiazolidin-(5Z)-ylidenemethyl]phenoxyacetic acid ethyl ester according to GP13, GP14 and GP16: LC/MS (an10p8): Rt 2.1 min, m/z 451 $[M + H]^+$.




4-Bromo-2-[3-(4-chlorobenzyl)-5-methyl-2,4-dioxothiazolidin-5-ylmethyl]-phenoxyacetic acid. Prepared from 4-bromomethylpyridine according to GP13, GP14, GP15 and GP16 (yield: 29 mg, 15%): LC/MS (an10p8): Rt 3.0 min, m/z 496 $[M - H]^-$; 1H NMR (DMSO- d_6): 1.71 (s, 3H), 3.24 (d, $J = 13.8$ Hz, 1H), 3.39 (d, $J = 13.8$ Hz, 1H), 4.63-4.68 (m, 4H), 6.86 (d, $J = 8.6$ Hz, 1H), 7.13-7.43 (m, 6H), 13.08 (br s, 1H).

**D147****4-Bromo-2-[3-(2,6-dichlorobenzyl)-5-methyl-2,4-dioxothiazolidin-5-**

ylmethyl]phenoxyacetic acid. Prepared from 2,6-dichlorobenzylbromide according to GP13, GP14, GP15 and GP16 to give 21.1 mg of the title compound: LC/MS

(an10n8): Rt 2.9 min, m/z 532 [M - H]⁻; ¹H NMR (DMSO-*d*₆): δ 1.63 (s, 3H), 3.16 (d, J = 13.6 Hz, 1H), 3.40 (d, J = 13.6 Hz, 1H), 4.65 (s, 2H), 4.92 (s, 2H), 6.86 (d, J = 8.9 Hz, 1H), 7.21 (d, J = 2.5 Hz, 1H), 7.35-7.48 (m, 4H), 12.38 (br s, 1H).

**D148****4-Bromo-2-[3-(2-chlorobenzyl)-5-methyl-2,4-dioxothiazolidin-5-**

ylmethyl]phenoxyacetic acid. Prepared from 2-chlorobenzylbromide according to GP13, GP14, GP15 and GP16 to give 22.0 mg of the title compound: LC/MS

(an10n8): Rt 2.8 min, m/z 498 [M - H]⁻; ¹H NMR (DMSO-*d*₆): δ 1.76 (s, 3H), 3.28 (d, J = 13.7 Hz, 1H), 3.43 (d, J = 13.7 Hz, 1H), 4.67 (d, J = 3.2 Hz, 2H), 4.73 (s, 2H), 6.81 (d, J = 8.9 Hz, 1H), 6.90 (d, J = 8.7 Hz, 1H), 7.24-7.36 (m, 3H), 7.43-7.50 (m, 2H), 12.18 (br s, 1H).

Biological Assays**Materials and Methods**

Generation/origin of the cDNA Constructs. The coding sequence of the human CRTH2 receptor (genbank accession no NM_004778) was amplified by PCR from a human hippocampus cDNA library and inserted into the pcDNA3.1(+) expression vector (invitrogen) via 5' HindIII and 3' EcoRI. To generate a CRTH2-Renilla luciferase (CRTH2-Rluc) fusion protein, the CRTH2 coding sequence without a STOP codon and Rluc were amplified, fused in frame by PCR and subcloned into the pcDNA3.1(+)Zeo expression vector (invitrogen). Human β-arrestin2 (β-arr2) N-terminally tagged with GFP² (βarr2-GFP²) and Renilla luciferase were purchased from BioSignal Packard Inc, (Montreal, Canada). The sequence identity of the

construct was verified by restriction endonuclease digests and sequencing in both directions on an ABI Prism (Applied Biosystems, Foster City, CA).

Sequence ID CRTH2 (protein sequence):

MSANATLKPLCPILEQMSRLQSHSNTSIRYIDHAAVLLHGLASLLGLVEN
GVILFVVGCRMRTVVTWVLHLALS~~DLLASASLPFFTYFLAVGHSWELG~~
TTF~~CKLHSSIFFLNMFASGFLLSAISLDRCLQVVRPVWAQNHRTVAAAHK~~
VCLVLWALAVLNTVPYFVFRDTISRDLGRIMCYYNVLLNPGPDRDATCN
SRQAALAVSKFLLAFLVPLAIIASSHAAVSLRLQHRGRRRPGRFVRLVAA
VVAAFALCWGPYHVFSLE~~ARAHANPGLRPLVWRGLPFVTSLAFFNSVAN~~
PVLYVLTCPDMLRKLRRSLRTVLESVLVDDSELGGAGSSRRRRTSSTARS
ASPLALCSRPEEPRGP~~ARLLGWLLGSCAASPQTGPLNRALSSTSS~~

Sequence ID CRTH2 (nucleotide sequence):

```
atgtcggc
caacgccaca ctgaagccac tctgccccat cctggagcag atgagccgtc
tccagagcca
cagcaacacc agcatccgct acatcgacca cgcggccgtg ctgctgcacg
ggctggcctc
gctgctgggc ctggtggaga atggagtcac cctcttcgtg gtgggctgcc
gcatgcgcca
gaccgtggtc accacctggg tgctgcacct ggcgctgtcc gacctgttgg
cctctgcttc
cctgcccttc ttcacctact tcttgccgtt gggccactcg tgggagctgg
gcaccacctt
ctgcaaactg cactcctcca tcttctttct caacatgttc gccagcggct
tctgctcag
cgccatcagc ctggaccgct gcctgcaggt ggtgcggccg gtgtgggccc
agaaccaccg
caccgtggcc gcggcgcaca aagtctgcct ggtgctttgg gcactagcgg
tgctcaacac
ggtgccctat ttctgtgttc gggacaccat ctgcggctg gacgggcccga
ttatgtgcta
ctacaatgtg ctgctcctga acccggggcc tgaccgcgat gccacgtgca
actcgcgcca
ggcgccctg gccgtcagca agttcctgct ggccttcctg gtgccgctgg
cgatcatcgc
ctcgagccac gcggccgtga gcctgcggtt gcagcaccgc ggccgccggc
ggccaggccg
cttcgtgcgc ctggtggcag ccgtcgtggc cgccttcgcg ctctgctggg
ggccctacca
cgtgttcagc ctgctggagg cgcgggcccga cgcaaaccgc gggctgcggc
cgctcgtgtg
gcgcgggctg cccttcgtca ccagcctggc cttcttcaac agcgtggcca
accggtgct
ctacgtgctc acctgccccg acatgctgcg caagctgcgg cgctcgtgc
gcacggtgct
ggagagcgtg ctggtggacg acagcgagct ggggtggcgc ggaagcagcc
gccgccgccc
cacctcctcc accgcccgtc cggcctcccc tttagctctc tgcagccgcc
cggaggaacc
gcggggcccc gcgcgtctcc tcggtgggt getgggcagc tgcgcagcgt
ccccgcagac
```

gggccccctg aaccgggcgc tgagcagcac ctcgagttag

Cell Culture and Transfection. COS-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) 1885 supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 1000 µg/ml streptomycin, and kept at 37°C in a 10% CO₂ atmosphere. HEK293 cells were maintained in Minimum Essential medium (MEM) supplemented with 10% (v/v) heat inactivated fetal calf serum (HIFCS), 2mM Glutamax™-I, 1% non essential amino acids (NEAA), 1% sodium pyruvate and 10 µg/ml gentamicin. For binding experiments, COS7 cells were transiently transfected with the CRTH2 receptor using a calcium phosphate-DNA coprecipitation method with the addition of chloroquine (as described by Holst et al., 2001+). To perform the functional Bioluminescence Resonance Energy Transfer (BRET) assays, a HEK293 cell clone stably expressing β arr2-GFP² and CRTH2-Rluc was generated (CRTH2-HEK293 cells).

Binding assay. 24h after transfection COS-7 cells were seeded into 96well plates at a density of 30.000 cells/well. Competition binding experiments on whole cells were then performed about 18-24 h later using 0.1 nM [³H]PGD2 (NEN, 172 Ci/mmol) in a binding buffer consisting of HBSS (GIBCO) and 10 mM HEPES. Competing ligands were diluted in DMSO which was kept constant at 1% (v/v) of the final incubation volume. Total and nonspecific binding were determined in the absence and presence of 10 µM PGD2. Binding reactions were routinely conducted for 3 h at 4°C and terminated by 2 washes (100 µl each) with ice cold binding buffer. Radioactivity was determined by liquid scintillation counting in a TOPCOUNTER (Packard) following over night incubation in Microscint 20. Stable HEK293 cells were seeded at a density of 30.000 cells/well 18-24 h prior to the binding assay which was performed essentially as described for COS7 cells above. Determinations were made in duplicates.

BRET assay. Functional BRET assays were performed on HEK293 cells stably expressing human CRTH2-Rluc and GFP²- β -arr2. Prior to their use in the BRET assay cells were detached and re-suspended in D-PBS with 1000 mg/L L-Glucose at a density of 2×10^6 cells/mL. DeepBlueC™ was diluted to 50 µM in D-PBS with 1000 mg/L L-Glucose (light sensitive). 100 µL of cell suspension was transferred to wells in a 96-well microplate (white OptiPlate) and placed in the Mithras LB 940 instrument (BERTHOLD TECHNOLOGIES, Bad Wildbad, Germany). 12 µL/well agonist was

then injected by injector 1 and 10 μL /well DeepBlueC™ was injected simultaneously by injector 2. Five seconds after the injections the light output from the well was measured sequentially at 400 nm and 515 nm, and the BRET signal (mBRET ratio) was calculated by the ratio of the fluorescence emitted by GFP²- β -arr2 (515 nm) over the light emitted by the receptor-Rluc (400 nm). Antagonists were added before placing the microplates into the Mithras LB 940 and allowed to incubate for 15 minutes prior to the addition of agonist and DeepBlueC™. Compounds were dissolved in DMSO and the final DMSO concentration was kept constant at 1% in the assay.

Human eosinophil shape change assay. Blood was sampled from healthy volunteers according to a protocol approved by the Ethics Committee of the University of Graz and processed as described previously (Bohm et al., 2004). Preparations of polymorphonuclear leukocytes (containing eosinophils and neutrophils) were prepared by dextran sedimentation of citrated whole blood and Histopaque gradients. The resulting cells were washed and resuspended in assay buffer (comprising PBS with Ca^{2+} / Mg^{2+} supplemented with 0.1% BSA, 10 mM HEPES and 10 mM glucose, pH 7.4) at 5×10^6 cells/mL. Cells were incubated with the antagonists or vehicle (PBS or DMSO) for 10 min at 37°C and then stimulated with various concentration of the agonists (PGD2 or eotaxin) for 4 min at 37°C. To stop the reaction, samples were transferred to ice and fixed with 250 μL of fixative solution. Samples were immediately analyzed on a FACSCalibur flow cytometer (Becton Dickinson) and eosinophils were identified according to their autofluorescence in the FL-1 and FL-2 channels. Shape change responses were quantified as percentage of the maximal response to PGD2 or eotaxin in the absence of an antagonist.

Materials

Tissue culture media and reagents were purchased from the Gibco invitrogen corporation (Breda, Netherlands). PGD2 was obtained from Cayman and [3H]PGD2 from NEN.

Data analysis

Curve analysis was performed with the GraphPadPrism software 3.0 (Graphpad Prism Inc., San Diego, USA) and IC_{50} values were calculated as a measure of the antagonistic potencies.

References

Holst B, Hastrup H, Raffetseder U, Martini L, Schwartz TW. Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis. J Biol Chem. 2001 Jun 8;276(23):19793-9. Epub 2001 Feb 22.

Biological data:

Compounds were tested in the receptor binding assay and the functional antagonist assay described below, and their IC_{50} values were assessed. The compounds are grouped in three classes:


A: IC_{50} value lower than 0.5 μ M

B: IC_{50} value between 0.5 μ M and 5 μ M

C: IC_{50} value higher than 5 μ M

Tables 1 to 7 give the biological test results for the compounds synthesised above and for some additional compounds acquired from commercial sources. The ability of the compounds above to inhibit prostaglandin D2 induced eosinophil shape change is demonstrated by the examples in Figure 1.

Table 1




	A	R1	R2	R3	R4	R5	R6	R7	R8	R9	X	Y	Binding IC_{50}	Antag. IC_{50}
D1	COOH	Br	H	H	H	H	H	H	H	H	C	C	A	A
D2	COOH	H	H	H	H	H	H	H	H	H	C	C	A	B
D3	COOH	F	H	H	H	H	H	H	H	H	C	C	A	B
D4	Tetrazole	Br	H	H	H	H	H	H	H	H	C	C	A	C
D5	COOH	Ph	H	H	H	H	H	H	H	H	C	C	A	A
D6	COOH	Br	H	H	H	H	H	H	H	-	N	C	A	A
D7	COOH	Br	H	H	H	H	H	OMe	H	H	C	C	A	A
D8	COOH		H	H	H	H	H	H	H	H	C	C	A	B
D9	COOH		H	H	H	H	H	H	H	H	C	C	A	A
D10	COOH	Cl	H	H	H	H	H	H	H	H	C	C	A	B

D11	COOH	Me	H	H	H	H	H	H	H	H	C	C	A	B
D12	COOH	Cl	Me	H	H	H	H	H	H	H	C	C	B	C
D13	COOH	Cl	H	Cl	H	H	H	H	H	H	C	C	C	C
D14	COOH	Br	H	H	H	Cl	H	H	H	H	C	C	C	A
D15	COOH	Br	H	H	H	H	Cl	H	H	H	C	C	A	A
D16	COOH	Br	H	H	H	H	H	Br	H	H	C	C	A	A
D17	COOH	Br	H	H	H	H	H	Cl	H	H	C	C	A	A
D18	COOH	Br	H	H	H	Et	H	H	H	H	C	C	A	A
D19	COOH	NO ₂	H	H	H	H	H	Cl	H	H	C	C	A	A
D20	COOH	NO ₂	H	H	H	H	H	H	H	H	C	C	A	A
D21	COOH	Br	H	H	H	Br	H	H	H	H	C	C	A	A
D22	COOH	Br	H	H	H	F	H	H	H	H	C	C	A	A
D23	COOH	Br	H	H	H	CF ₃	H	H	H	H	C	C	A	A
D24	COOH	Br	H	H	H	H	Br	H	H	H	C	C	A	A
D25	COOH	Br	H	H	H	H	CF ₃	H	H	H	C	C	A	A
D26	COOH	Br	H	H	H	Cl	H	Cl	H	H	C	C	A	A
D27	COOH	NO ₂	H	H	H	Cl	H	H	H	H	C	C	A	A
D28	COOH	NO ₂	H	H	H	Br	H	H	H	H	C	C	A	A
D29	COOH	Br	H	H	H	Cl	H	H	H	Cl	C	C	A	A
D30	COOH	Et	H	H	H	Br	H	H	H	H	C	C	A	A
D31	COOH	i-Pr	H	H	H	Cl	H	H	H	H	C	C	A	A
D32	COOH	Br	H	H	H	H	H	OCF ₃	H	H	C	C	A	A
D33	COOH	Br	H	H	H	Br	H	Br	H	H	C	C	A	A
D34	COOH	Br	H	H	H	Cl	H	Br	H	H	C	C	A	A
D35	COOH	Br	H	H	H	Cl	H	Cl	H	Cl	C	C	A	A
D36	COOH	OMe	H	H	H	H	H	H	H	H	C	C	A	B
D37	COOH	Br	H	H	Me	H	H	H	H	H	C	C	A	A
(S)- D37	COOH	Br	H	H	Me	H	H	H	H	H	C	C	A	A
D38	COOH	Br	H	H	Me	Cl	H	H	H	H	C	C	A	A
D39	COOH	Br	H	H	Me	Cl	H	H	H	Cl	C	C	A	A
D40	COOH	Br	H	H	H	CN	H	H	H	H	C	C	A	A
D41	COOH	Br	H	H	H	OEt	H	H	H	H	C	C	A	A
D42	COOH	Br	H	H	H	Et	H	Br	H	H	C	C	A	A
D43	COOH	Br	H	H	H	OPh	H	H	H	H	C	C	A	A
D44	COOH	Br	H	H	H	SMe	H	H	H	H	C	C	A	A
D45	COOH	Br	H	H	H	Br	H	Me	H	H	C	C	A	A
D46	COOH	Br	H	H	Me	Et	H	Br	H	H	C	C	A	A
D47	COOH	Br	H	H	Me	OPh	H	H	H	H	C	C	A	A
D48	COOH	Br	H	H	Me	OEt	H	H	H	H	C	C	A	A
D49	COOH	Br	H	H	Me	SMe	H	H	H	H	C	C	A	A
D50	COOH	Br	H	H	Me	Br	H	Me	H	H	C	C	A	A
D51	COOH	Br	H	H	Me	OPh	H	H	H	H	C	C	A	A

D52	COOH	Br	H	H	H	OCF ₃	H	H	H	H	C	C	A	A
D53	COOH	Et	H	H	H	Me	H	H	H	Me	C	C	A	A
D54	COOH	Br	H	H	H	Me	H	Me	H	H	C	C	A	A
D55	COOH	Br	H	H	Me	Me	H	Me	H	H	C	C	A	A
D58	COOH	Br	H	H	H	Me	H	Cl	H	H	C	C	A	A
D59	COOH	Br	H	H	H	Cl	H	H	Cl	H	C	C	A	A
D60	COOH	Br	H	H	H	OMe	H	H	H	H	C	C	A	A
D61	COOH	Br	H	H	H	H	Cl	Cl	H	H	C	C	A	A
D62	COOH	Br	H	H	Me	Me	H	Cl	H	H	C	C	A	A
D63	COOH	Br	H	H	Me	Cl	H	Cl	H	H	C	C	A	A
D64	COOH	Br	H	H	Me	H	Cl	Cl	H	H	C	C	A	A
D65	COOH	Br	H	H	Me	OMe	H	H	H	H	C	C	A	A
D66	COOH	NH ₂	H	H	H	H	H	H	H	H	C	C	B	A
D67	COOH	Br	H	H	Me	Cl	H	Br	H	H	C	C	A	A
D68	COOH	Br	H	H	Me	Cl	H	Cl	H	Cl	C	C	A	A
D69	COOH	Br	H	H	Me	Br	H	Br	H	H	C	C	A	A
D70	COOH	Br	H	H	H	Et	H	H	H	Et	C	C	A	A
D71	COOH	Br	H	H	H	Me	H	H	H	Me	C	C	A	A
D72	COOH	Br	H	H	H	Et	H	H	H	Me	C	C	A	A
D73	COOH	Br	H	H	H	i-Pr	H	H	H	H	C	C	A	A
D74	COOH	EtO	H	H	H	H	H	H	H	H	C	C	B	C
D75	COOH	n-Bu	H	H	H	H	H	H	H	H	C	C	A	C
D76	COOH	Br	H	H	H	Cl	H	H	H	Me	C	C	A	A
D77	COOH	Br	H	H	Me	Me	H	H	H	Me	C	C	A	A
D78	COOH	Br	H	H	Me	Et	H	H	H	Et	C	C	A	A
D79	COOH	Br	H	H	Me	i-Pr	H	H	H	H	C	C	A	A
D80	COOH	Br	H	H	H	Cl	H	H	H	Cl	C	N	A	A
D81	COOH	Br	H	H	H	H	H	CF ₃	H	H	C	C	A	A

Table 2




	n	X	R1	R2	R3	R4	R5	Binding IC ₅₀	Antag. IC ₅₀
D83	0	O	H	H	H	H	H	A	C
D84	0	O	H	H	OMe	H	H	A	B
D85	0	O	H	H	Cl	H	H	A	C

D86	0	O	H	OMe	H	H	H	A	A
D87	0	O	H	H	OEt	H	H	A	C
D88	1	O	H	H	H	H	H	A	A
D89	1	O	H	OMe	H	H	H	A	A
D90	1	O	Cl	H	F	H	H	A	A
D91	1	O	Cl	H	H	H	Cl	A	A

D92	1	O	H	H	OMe	H	H	A	A
D93	0	S	H	H	H	H	H	A	A
D94	1	S	H	H	Cl	H	H	A	A

Table 3




	n	R1	R2	R3	R4	R5	Binding IC₅₀	Antag. IC₅₀
D99	0	H	H	H	H	H	A	A

D100	0	H	H	F	H	H	A	A
D101	0	H	H	OMe	H	H	A	A
D102	0	H	H	Cl	H	H	A	A
D103	0	H	H	OCF ₃	H	H	A	A
D104	0	H	OMe	H	H	H	A	A
D105	0	H	Cl	H	H	H	A	A
D106	0	H	H	CF ₃	H	H	A	A
D107	0	OMe	H	H	H	H	A	A
D108	0	Cl	H	H	H	H	A	A
D109	0	H	CF ₃	H	CF ₃	H	A	C
D110	0	Cl	H	H	H	Cl	A	A
D111	0	H	H	OPh	H	H	A	A
D112	0	H	CF ₃	H	H	H	A	A
D113	1	H	H	OCF ₃	H	H	A	A
D114	1	H	H	Cl	H	H	A	A
D115	1	H	H	H	H	H	A	A

D116	1	H	H	F	H	H	A	A
D117	1	H	F	H	F	H	A	A
D118	1	H	H	OMe	H	H	A	A
D119	1	H	OMe	H	H	H	A	A
D120	1	Cl	H	H	H	H	A	A
D121	1	Cl	H	H	H	Cl	A	A
D122	1	Cl	H	Cl	H	H	A	A
D123	1	H	Cl	Cl	H	H	A	A
D124	1	H	OMe	OMe	H	H	A	A
D125	1	H	OMe	H	H	H	A	C
D126	1	H	H	Me	H	H	A	A
D127	1	CF ₃	H	H	H	H	A	A
D128	1	H	OMe	H	OMe	H	A	B
D129	0	Cl	H	Cl	H	H	A	A
D130	1	H	Cl	H	H	H	A	A
D131	1	H	H	NHAc	H	H	A	A

Table 4



	n	R1	R2	R3	R4	R5	Activity	Binding IC ₅₀	Antag. IC ₅₀
D134	0	H	H	4-PhOMe	H	H	A	A	A
D135	0	H	H	Cl	H	H	A	A	A
D136	0	H	Cl	H	H	H	A	A	A
D137	0	Cl	H	H	H	H	A	A	A
D138	0	H	H	H	H	H	A	A	C


Table 5

	Structure	Binding IC ₅₀	Antag. IC ₅₀
D56		A	A
D57		A	A
D82		A	A
D95		A	A
D96		A	B
D97		A	A
D98		A	
D132		A	A
D133		A	C






Table 6

	Structure	Binding IC ₅₀	Antag. IC ₅₀
D139		A	A

D140		A	B
D141		A	A
D142		A	A
D143		A	A
D144		A	A
D145		A	A
D146		A	A


Table 7

Cmp	R1	R2	Binding IC₅₀	Antag. IC₅₀
D149	H		A	A
D150	Br		A	C
D151	Br		A	C

D152	Br		A	B
D153	H		B	C
D154	H		A	A
D155	H		A	B
D156	H		A	B

Claims:

1. Use of a compound of formula (I) or a salt, hydrate or solvate thereof in the manufacture of a composition for the treatment of disease responsive to modulation of CRTH2 receptor activity:



wherein

A represents a carboxyl group $-\text{COOH}$, or a carboxyl bioisostere;

A₁ is hydrogen or methyl;

ring Ar¹ is an optionally substituted phenyl ring or 5- or 6-membered monocyclic heteroaryl ring, in which $\text{AA}_1\text{CHO}-$ and **L2** are linked to adjacent ring atoms;

rings Ar², Ar³ each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted;

t is 0 or 1;

L2 and L3 each independently represent a divalent radical of formula $-(\text{Alk}^1)_m-(\text{Z})_n-(\text{Alk}^2)_p$ wherein

m, n and p are independently 0 or 1,

Alk¹ and Alk² are independently optionally substituted straight or branched chain $\text{C}_1\text{-C}_3$ alkylene or $\text{C}_2\text{-C}_3$ alkenylene radicals which may contain a compatible $-\text{O}-$, $-\text{S}-$ or $-\text{NR}-$ link wherein R is hydrogen or $\text{C}_1\text{-C}_3$ alkyl, and

Z is $-\text{O}-$; $-\text{S}-$; $-\text{C}(=\text{O})-$; $-\text{SO}_2-$; $-\text{SO}-$; $-\text{NR}-$, $-\text{NRSO}_2-$, $-\text{SO}_2\text{NR}-$,

-C(=O)NR-, -NRC(=O)-, -NRCONH-, -NHCONR-, -NRC(=NR)NH-,
 -NHC(=NR)NR-, -C(R)=N-NR-, or -NR-N=C(R)- wherein R is hydrogen or
 C₁-C₃ alkyl; or a divalent 5- or 6-membered monocyclic carbocyclic or
 heterocyclic radical,

PROVIDED THAT

- (A) the total length of L2 and L3 does not exceed that of an unbranched saturated chain of 10 carbon atoms; and
- (B) L2 is not -C(=O)-, -C(=O)NR-, or -NRC(=O)- when Ar² is optionally substituted phenyl; and
- (C) (a) L2 is not a bond and (b) p in L2 is not 0 when n is 1 and Z is aryl or heteroaryl, and
- (D) (a) L2 is not -O-, -SO₂-, -NR-, -CHR^XR^Y- or -CH(R^X)(OR^Y)-, wherein R^X and R^Y are independently hydrogen, halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, or C₃-C₇ cycloalkyl, or join to form a ring, and (b) when p is 1 and n is 1 and Z is aryl or heteroaryl then Alk² is not -CHR^XR^Y- or -CH(R^X)(OR^Y)-, wherein R^X and R^Y are independently hydrogen, halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, or C₃-C₇ cycloalkyl, or join to form a ring.
2. A method of treatment of disease responsive to modulation of CRTH2 receptor activity comprising administering to a subject suffering such disease and effective amount of a compound as defined in claim 1.
3. Use as claimed in claim 1 or a method as claimed in claim 2, wherein, in the compound (I), (i) the length of each of L2 and L3 does not exceed that of an unbranched saturated chain of 5 carbon atoms and (ii) the total length of L2 and L3 does not exceed that of an unbranched saturated chain of 7 carbon atoms, and (iii) neither of L2 and L3 includes more than two R substituents different from hydrogen,
4. Use or a method as claimed in any of the preceding claims wherein, in the compound (I), A₁ is hydrogen and Z is -O-, -S-, -C(=O)-; -SO₂-; -SO-, -NR-, -NRSO₂- -C(=O)NR-, -NRCONH-, -NRC(=NR)NH-, or -C(R)=N-NR-, wherein R is hydrogen or

C₁-C₃ alkyl; or a divalent 5- or 6-membered monocyclic carbocyclic or heterocyclic radical.


5. Use or a method as claimed in any of claims 1 to 4 wherein, in the compound (I), L2 is -N=CR-, -OCR₂C(=O)NR-N=CR-, -C(=O)NR-, -N=CR-, -C(=O)-, -CH=CHC(=O)-, -(CH₂)₀₋₃NRC(=O)-, -NRC(=O)(CH₂)₀₋₃-, -O-N=CH-, -CH₂NRCH₂-, -NR(CH₂)₁₋₃-, -(CH₂)₁₋₃NR-, -S-, -CH₂OCH₂-, -O(CH₂)₁₋₃-, -(CH₂)₁₋₃O-, -CH₂SCH₂-, -S(CH₂)₀₋₃-, -(CH₂)₀₋₃S-, a divalent (C₂-C₆)alkylene radical, a divalent (C₂-C₆)alkenylene radical, or a divalent (C₂-C₆)alkynylene radical, wherein R is hydrogen or C₁-C₃ alkyl.


6. Use or a method as claimed in any of claims 1 to 4 wherein, in the compound (I), L2 is -NRN=CH-, -ON=CH-, or -N=CH-.

7. Use or a method as claimed in any of claims 1 to 4 wherein, in the compound (I), L2 is -C(=O)-.

8. Use or a method as claimed in any of claims 1 to 4 wherein, in the compound (I), L2 is -NHC(=O)- or -C(=O)NH-.


9. Use or a method as claimed in any of claims 1 to 4 wherein, in the compound (I), L2 is a divalent radical selected from one of the following formulae, wherein either (i) the bond marked * is attached to Ar² while the bond marked ** is attached to Ar¹, or (ii) the bond marked * is attached to Ar¹ while the bond marked ** is attached to Ar²:





wherein R is hydrogen or C₁-C₃ alkyl.

10. Use or method as claimed in claim 9 wherein, in the compound (I), A1 is hydrogen and L2 has one of the following formulae wherein the bond marked * is attached to Ar² while the bond marked ** is attached to Ar¹:



wherein R is hydrogen or C₁-C₃ alkyl.

11. Use or method as claimed in any of the preceding claims wherein the disease is one associated with elevated levels of prostaglandin D2 (PGD2) or one or more active metabolites thereof.
12. Use or method as claimed in any of claims 1 to 10 wherein the disease is an inflammatory, autoimmune, respiratory or allergy disease.
13. Use or method as claimed in any of claims 1 to 10 wherein the disease is selected from asthma, rhinitis, allergic airway syndrome, allergic rhinobronchitis, bronchitis, chronic obstructive pulmonary disease (COPD), nasal polyposis, sarcoidosis, farmer's lung, fibroid lung, cystic fibrosis, chronic cough, conjunctivitis, atopic dermatitis, Alzheimer's disease, amyotrophic lateral sclerosis, AIDS dementia complex, Huntington's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, Guillain-Barre syndrome, chronic demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathy, multiple sclerosis, encephalomyelitis, panencephalitis, cerebellar degeneration and encephalomyelitis, CNS trauma, migraine, stroke, rheumatoid arthritis, ankylosing spondylitis, Behçet's Disease, bursitis, carpal tunnel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, dermatomyositis, Ehlers-Danlos Syndrome (EDS), fibromyalgia, myofascial pain, osteoarthritis (OA), osteonecrosis, psoriatic arthritis, Reiter's syndrome (reactive arthritis), sarcoidosis, scleroderma, Sjogren's Syndrome, soft tissue disease, Still's Disease, tendinitis, polyarteritis Nodosa, Wegener's Granulomatosis, myositis (polymyositis dermatomyositis), gout, atherosclerosis, lupus erythematosus, systemic lupus erythematosus (SLE), type I diabetes, nephritic syndrome, glomerulonephritis, acute and chronic renal failure, eosinophilia fascitis, hyper IgE syndrome, sepsis, septic shock, ischemic reperfusion injury in the heart, allograft rejection after transplantations, and graft versus host disease.
14. Use or method as claimed in any of claims 1 to 10 wherein the disease is selected from asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis,
15. Use or method as claimed in any of the preceding claims wherein, in the compound (I), ring Ar² is (i) an optionally substituted phenyl or naphthyl ring; (ii) a phenyl ring fused to a 5- or 6-membered nitrogen-containing heterocyclic ring, either or both of such rings being optionally substituted; (iii) an optionally substituted nitrogen-containing 5- or 6-membered heteroaryl ring; or (iv) a nitrogen-containing 5-

or 6-membered heterocyclic ring fused to a phenyl ring, either of which rings being optionally substituted.

16. Use or method as claimed in claim 15 wherein, in the compound (I), ring Ar² is optionally substituted phenyl, pyridyl, pyrimidyl, diazolyl, thiazolyl, oxazolyl, triazinyl, quinolinyl, pyrrollyl, furanyl, thiazolyl.

17. V as claimed in claim 15 or claim 16 wherein, in the compound (I), optional substituents in Ar² are selected from fluoro, chloro, bromo, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₃alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, and nitro.

18. Use or method as claimed in any of the preceding claims wherein, in the compound (I), Ar¹ is a 5- or 6-membered nitrogen-containing heteroaryl ring, optionally substituted.

19. Use or method as claimed in any of claims 1 to 17 wherein in the compound (I), Ar¹ is a phenyl ring and L3 is linked to the 4-position thereof relative to the ACHA₁O⁻ radical.

20. Use or method as claimed in any of the preceding claims wherein in compound (I), t is 1 and Ar³ is a 5- or 6-membered heteroaryl ring, optionally substituted.


21. Use or method as claimed in any of the preceding claims wherein in compound (I), t is 1 and Ar³ is a phenyl ring, optionally substituted.

22. Use or method as claimed in any of the preceding claims wherein in compound (I), any optional substituents in ring Ar¹ or Ar³ are selected from fluoro, chloro, bromo, iodo, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, (C₁-C₃alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, C₁-C₆ alkyl, C₁-C₆ alkoxy, cycloalkyl, aryl, aryloxy, aryl(C₁-C₆)⁻ or aryl(C₁-C₆ alkoxy)⁻.

23. Use or method as claimed in any of claims 1 to 19 wherein in compound (I), t is 0 and L3 is a bond.


24. Use or method as claimed in any of the preceding claims wherein, in the compound (I), A is $-\text{COOH}$.

25. Use or method as claimed in any of claims 1 to 23 wherein, in the compound (I), A is a carboxyl bioisostere selected from $-\text{SO}_2\text{NHR}$ and $-\text{P}(=\text{O})(\text{OH})(\text{OR})$ wherein R is hydrogen methyl or ethyl, $-\text{SO}_2\text{OH}$, $-\text{P}(=\text{O})(\text{OH})(\text{NH}_2)$, $-\text{C}(=\text{O})\text{NHCN}$ and groups of formulae:



26. Use or method as claimed in any of the preceding claims wherein, in the compound (I), A_1 is hydrogen.


27. A compound of formula (IV) or a salt, hydrate or solvate thereof



wherein A, A_1 , L3, Ar^3 , Ar^2 , and t are as defined in claim 1 or claim 2,


R_{13} represents hydrogen or one or more optional substituents,


L2 is a divalent radical selected from the following wherein either (i) the bond marked * is attached to Ar^2 while the bond marked ** is attached to Ar^1 , or (ii) the bond marked * is attached to Ar^1 while the bond marked ** is attached to Ar^2 :



wherein R is hydrogen or C₁-C₃ alkyl.

28. A compound as claimed in claim 26 wherein A₁ is hydrogen and L2 is selected from the following wherein the bond marked * is attached to Ar² while the bond marked ** is attached to Ar¹:






wherein R is hydrogen or C₁-C₃ alkyl.


29. A compound as claimed in claim 27 or claim 28 wherein A is -COOH.

30. A compound as claimed in claim 27 or claim 28 wherein A is a carboxyl bioisostere selected from -SO₂NHR and -P(=O)(OH)(OR) wherein R is hydrogen methyl or ethyl, -SO₂OH, -P(=O)(OH)(NH₂), -C(=O)NHCN and groups of formulae:




31. A compound as claimed in any of claims 27 to 30 wherein R₁₃ represents one or more substituents selected from fluoro, chloro, bromo, iodo, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, (C₁-C₃alkyl)SO₂-, NH₂SO₂-, (C₁-C₃alkyl)NHSO₂-, (C₁-C₃alkyl)₂NSO₂-, C₁-C₆ alkyl, C₁-C₆ alkoxy, cycloalkyl, aryl, aryloxy, aryl(C₁-C₆)- or aryl(C₁-C₆ alkoxy)-.

32. A compound of formula (IVA) or a salt, hydrate or solvate thereof




wherein A, L3, t, Ar³, R₁₃ are as defined in any of claims 26 to 30 and R₁₄ is optionally substituted phenyl or 5- or 6- membered heteroaryl.

33. A compound of formula (IVB) or a salt hydrate or solvate thereof



wherein L3, t, and Ar³ are as defined in any of claims 26 to 30 and R₁₄ is optionally substituted phenyl or 5- or 6- membered heteroaryl.

34. A compound of formula (IVC) or a salt hydrate or solvate thereof



wherein R₁₃ represents a substituent selected from fluoro, chloro, bromo, iodo, (C₁-C₆)alkyl, trifluoromethyl, (C₁-C₆)alkoxy, (C₁-C₆)alkylmercapto, trifluoromethoxy, trifluoromethylthio, dimethylamino, cyano, (C₁-C₃alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, and nitro, and R₁₄ is optionally substituted phenyl or 5- or 6- membered heteroaryl.

35. A compound as claimed in claim 34 wherein R₁₄ is a 2-substituted, 2,4-disubstituted, 2,6-disubstituted or 2,4,6-trisubstituted phenyl ring where the substituents are selected from fluoro, chloro, bromo, iodo, (C₁-C₆)alkyl, trifluoromethyl, (C₁-C₆)alkoxy, (C₁-C₆)alkylmercapto, trifluoromethoxy, trifluoromethylthio, dimethylamino, (C₁-C₃alkyl)SO₂⁻, NH₂SO₂⁻, (C₁-C₃alkyl)NHSO₂⁻, (C₁-C₃alkyl)₂NSO₂⁻, and cyano

36. A compound as claimed in claim 34 wherein R₁₄ is a 2-substituted, 2,4-disubstituted, or 2,6-disubstituted phenyl ring where the substituents are selected

from fluoro, chloro, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, (C₁-C₃)alkylmercapto, trifluoromethoxy, trifluoromethylthio, and cyano.

37. A compound as claimed in claim 34 wherein R₁₄ is a 2-substituted or 2,6-disubstituted pyridyl ring where the substituents are selected from fluoro, chloro, (C₁-C₃)alkyl, trifluoromethyl, (C₁-C₃)alkoxy, (C₁-C₃)alkylmercapto, trifluoromethoxy, trifluoromethylthio, and cyano.

38. A compound as claimed in claim 34 wherein R₁₃ is selected from fluoro, chloro, bromo, iodo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethoxy and trifluoromethylthio, and R₁₄ is optionally substituted phenyl or optionally substituted 5- or 6- membered heteroaryl.

39. A compound as claimed in any of claims 27 to 38 wherein A₁ is hydrogen.

40. An enantiomer of a compound as claimed in any of claims 27 to 38 wherein A₁ is methyl, and the carbon atom to which it is attached has the S stereochemical configuration.

41. A compound as claimed in claim 27 selected from the group consisting of:
4-chloro-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetic acid,
4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxyacetic acid,
[4-bromo-2-(1-pyridin-2-yl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid,
{4-bromo-2-[1-(2-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(3-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(4-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(4-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(2-ethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(2-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(2-fluorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(2-trifluoromethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(3-bromophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(2,4-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{2-[1-(2-chlorophenyl)-1H-pyrazole-4-carbonyl]-4-nitrophenoxy}acetic acid,
{4-bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{2-[1-(2-bromophenyl)-1H-pyrazole-4-carbonyl]-4-ethylphenoxy}acetic acid,
{4-bromo-2-[1-(2,4-dibromophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,

{4-bromo-2-[1-(4-bromo-2-chlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-bromo-2-[1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
2-[4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]propionic acid,
(S)-2-[4-bromo-2-(1-phenyl-1H-pyrazole-4-carbonyl)phenoxy]propionic acid,
2-[4-Bromo-2-[1-(2-chlorophenyl)-1-H-pyrazole-4-carbonyl]phenoxy]propionic acid,
(S)-2-[4-Bromo-2-[1-(2-chlorophenyl)-1-H-pyrazole-4-carbonyl]phenoxy]propionic acid,
2-[4-Bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy]propionic acid,
(S)-2-[4-Bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy]propionic acid,
{4-Bromo-2-[1-(2-ethoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(4-bromo-2-ethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2-phenoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2-methylthiophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2-bromo-4-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
2-[4-Bromo-2-[1-(4-bromo-2-ethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy]propionic acid,
2-[4-Bromo-2-[1-(2-phenoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy]propionic acid,
(S)-2-[4-Bromo-2-[1-(2-phenoxyphenyl)-1H-pyrazole-4-carbonyl]phenoxy]propionic acid,
2-[4-Bromo-2-[1-(2-methylthio)-1H-pyrazole-4-carbonyl]phenoxy]propionic acid,
(S)-2-[4-Bromo-2-[1-(2-methylthio)-1H-pyrazole-4-carbonyl]phenoxy]propionic acid,
{4-Bromo-2-[1-(2,4-dimethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(4-chloro-2-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2,5-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
2-[4-Bromo-2-[1-(4-chloro-2-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy]propionic acid,
2-[4-Bromo-2-[1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy]propionic acid,
{4-Bromo-2-[1-(2,6-diethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2,6-dimethylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(2-ethyl-6-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,

{4-Bromo-2-[1-(2-chloro-6-methylphenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[1-(3,5-dichloropyridin-4-yl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid,
[4-Bromo-2-(1-naphthalen-1-yl-1H-pyrazole-4-carbonyl)phenoxy]acetic acid,
{4-Bromo-2-[2-(4-chlorobenzyl)thiazol-4-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(4-fluoro-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid,
{4-Bromo-2-[3-(2,6-dichloro-benzyl)-[1,2,4]oxadiazol-5-yl]-phenoxy}-acetic acid,
{4-Bromo-2-[3-(2-trifluoromethylbenzyl)-[1,2,4]oxadiazol-5-yl]phenoxy}-acetic acid,
4-Bromo-2-[3-(2,6-dichloro-phenyl)isoxazole-5-carbonyl]phenoxy}acetic acid,
{4-Bromo-2-[3-(1-phenylcyclopropyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,
{4-Bromo-2-[3-(2,4-dichlorophenyl)-[1,2,4]oxadiazol-5-yl]phenoxy}acetic acid,

and salts, hydrates and solvates thereof.

42. A pharmaceutical composition comprising a compound as claimed in any of claims 27 to 41, together with a pharmaceutically acceptable carrier.

1/1




Figure 1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/005884

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/415 A61K31/454 A61P29/00 A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 2005/018529 A (ASTRAZENECA AB; ASTRAZENECA UK LIMITED; BONNERT, ROGER, VICTOR; PATEL,) 3 March 2005 (2005-03-03) cited in the application abstract page 1, line 3 - line 5 page 14, line 24 - page 17, line 38 examples 1-68 claims 1-25</p> <p style="text-align: center;">----- -/--</p>	1-40, 42



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

10 October 2005

Date of mailing of the international search report

18/10/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Taylor, G.M.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/005884

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 2004/089885 A (ASTRAZENECA AB; BONNERT, ROGER; BROUGH, STEPHEN; DAVIES, ANDREW; LUKER) 21 October 2004 (2004-10-21) cited in the application abstract page 1, line 3 - line 5 page 11, line 11 - page 13, line 35 examples 1-170 claims 1-11	1-40,42
X	WO 01/21591 A (F. HOFFMANN-LA ROCHE AG) 29 March 2001 (2001-03-29) abstract page 41, line 3 - line 9 examples 1-34 claims 1-44	1-40,42
X	WO 99/57101 A (F. HOFFMANN-LA ROCHE AG) 11 November 1999 (1999-11-11) abstract page 52, line 14 - line 23 examples 1-30 claims 1-45	1-40,42
X	WO 94/13643 A (PFIZER INC; FARACI, WILLIAM, STEPHEN; WELCH, WILLARD, MCKOWAN, JR) 23 June 1994 (1994-06-23) abstract page 1, line 9 - line 20 page 4, line 18 - page 5, line 12 examples 1-18 claims 1-10	1-40,42
P,A	ULVEN T ET AL: "Minor Structural Modifications Convert the Dual TP/CRTH2 Antagonist Ramatroban into a Highly Selective and Potent CRTH2 Antagonist" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 48, no. 4, 24 February 2005 (2005-02-24), pages 897-900, XP002339598 ISSN: 0022-2623 the whole document	1-42

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/005884

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2005018529	A	03-03-2005	NONE	
WO 2004089885	A	21-10-2004	NONE	
WO 0121591	A	29-03-2001	AU 777470 B2	21-10-2004
			AU 7655800 A	24-04-2001
			BR 0014225 A	21-05-2002
			CA 2385447 A1	29-03-2001
			EP 1218346 A1	03-07-2002
			JP 2003509495 T	11-03-2003
			MX PA02002382 A	20-08-2002
			TR 200200778 T2	21-06-2002
			ZA 200201559 A	26-05-2003
WO 9957101	A	11-11-1999	AT 292118 T	15-04-2005
			AU 765030 B2	04-09-2003
			AU 4034899 A	23-11-1999
			BR 9911013 A	06-02-2001
			CA 2329065 A1	11-11-1999
			CN 1300282 A	20-06-2001
			DE 69924480 D1	04-05-2005
			EP 1075467 A1	14-02-2001
			HK 1037374 A1	10-12-2004
			HR 20000724 A1	30-06-2001
			HU 0101581 A2	28-03-2002
			ID 27535 A	12-04-2001
			JP 3590586 B2	17-11-2004
			JP 2002513784 T	14-05-2002
			MA 26627 A1	20-12-2004
			NO 20005535 A	02-11-2000
			NZ 507558 A	29-08-2003
			PL 344004 A1	10-09-2001
			TR 200003256 T2	20-04-2001
			TW 593282 B	21-06-2004
WO 9413643	A	23-06-1994	AT 175961 T	15-02-1999
			AU 690527 B2	30-04-1998
			AU 5454894 A	04-07-1994
			BR 9307659 A	29-06-1999
			CA 2150483 A1	23-06-1994
			CN 1092768 A	28-09-1994
			CZ 9501585 A3	17-01-1996
			DE 69323212 D1	04-03-1999
			DE 69323212 T2	27-05-1999
			DK 674624 T3	13-09-1999
			EG 20397 A	28-02-1999
			EP 0674624 A1	04-10-1995
			ES 2126661 T3	01-04-1999
			FI 935674 A	18-06-1994
			GR 3029568 T3	30-06-1999
			HU 67457 A2	28-04-1995
			IL 107946 A	24-09-1998
			JP 2862374 B2	03-03-1999
			JP 7509725 T	26-10-1995
			KR 170567 B1	18-02-1999
			MX 9308042 A1	31-08-1994
			NO 952395 A	16-08-1995
			NO 985494 A	16-08-1995

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/005884

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9413643	A	NZ 257770 A	24-02-1997
		PL 309356 A1	02-10-1995
		RU 2142946 C1	20-12-1999
		US 5712303 A	27-01-1998
		ZA 9309404 A	15-06-1995
<hr/>			